6902 corporate ad 7.5x10.indd 1 29/7/16 12:18thursday, 3:30 pm $100 amazon gift card friday, 10:15...

26902 Corporate Ad 7.5x10.indd 1 29/7/16 12:18

3

Colleagues, On behalf of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), I welcome you to the 2016 Annual Meeting! I would like to personally invite you to attend two great networking opportunities that you won’t want to miss. First, please attend our meeting kick-off event, the President’s Reception, at 5:30 pm on Wednesday, in the Grand Ballroom of the Hilton New Orleans Riverside. The following evening, please join me at 5:30 pm in the Hall of Research (Exhibition Center C) for an evening celebrating research at the Abstract Award Winner’s Reception, where you can enjoy refreshments while abstract award winners present their research. Both events start early, so you’ll have plenty of time to enjoy dinner later on at one of New Orleans’ many great restaurants.

This week you’ll learn from other EDX and neuromuscular specialists who are able to address your questions – no matter your career stage or level of expertise. While you’re here, make sure to:• Learn about insights and innovation in neuromuscular

medicine at this year’s plenary sessions, featuring sessions by topic experts addressing contemporary issues in clinical practice and research;

• Attend course lectures and symposia to hear experts discuss the latest breaking news;

• Ask practice-related questions in small, informal groups at the Ask the Expert sessions;

• Learn about cutting-edge advances from the researchers themselves, and advance your technical skills through hands-on workshops;

• Meet the authors of your favorite textbooks face-to-face during designated times at the AANEM Education Products Display.

On behalf of the AANEM Board, meeting committees, and staff, welcome to New Orleans, and we sincerely hope you enjoy all that our 2016 Annual Meeting has to offer.

Vern C. Juel, MD2016 President

Join us at the 2016 AANEM Annual Meeting!

This week you’ll learn from other EDX and neuromuscular

specialists who are able to address your questions – no

matter your career stage or level of expertise.

Vern C. Juel, MD2016 AANEM President

4

Contents3 President’s Letter4 Abbreviations5 Tips & Tools5 Registration Hours6 Exhibit Hall Hours6 Speaker Ready Room6 Meet the Authors7 WiFi Password7 Claim CME/CEU Credit:8 2016 Plenary Speakers9 Exhibit Hall Passport10 Sponsored Tours11 Self-Assessment Courses

12 Hotel Maps14 Meeting Sessions35 Social Event35 Silent Auction36 Exhibitor List37 Exhibit Booths43 Corporate Supporters44 Poster Hall Layout 45 Abstract Award Recipients46 Achievement Award Recipients47 President’s Research Initiative Awards48 Resident & Fellows Member Recognition

48 Foundation and IFCN Fellowship Awards49 Foundation Contributors50 Advocacy Contributors50 Corporate Circle Contributors51 Save the Date52 Disclosures56 Note Pages60 AANEM Meeting Committees, Boards, & Staff61 Faculty & Speaker Index

Abbreviations Used Throughout this BrochureAANEM: American Association of

Neuromuscular & Electrodiagnostic Medicine

ABMS: American Board of Medical Specialties

ABPN: American Board of Psychiatry & Neurology

ABPMR: American Board of Physical Medicine and Rehabilitation

ALS: Amyotrophic lateral sclerosis CIDP: Chronic inflammatory

demyelinatingpolyradiculoneuropathy

CK: Creatine kinaseCMS: Congenital Myasthenic SyndromeCNP: Clinical neurophysiologyCTS: Carpal tunnel syndromeEDX: Electrodiagnostic

EMG: ElectromyographyGAA: Acid alpha-glucosidaseGBS: Guillain-Barré syndromeHRDB: Heart rate variation during

deep breathingIOM: Intraoperative monitoringLEMS: Lambert Eatm myasthenic syndromeLGMD: Limb-girdle muscular dystrophyMEP: Motor evoked potentialMG: Myasthenia gravisMGFA: Myasthenia Gravis Foundation

of AmericaMND: Motor neuron disorderMRI: Magnetic resonance lmagingMSK: MusculoskeletalMUP: Motor unit action potentialMUNE: Motor unit number estimatesNCS: Nerve conduction study

NM: NeuromuscularNMDs: Neuromuscular disordersNMJ: Neuromuscular junctionPMR: Physical medicine and

rehabilitationQ-SART: Quantitative sudomotor axon

reflex testQST: Quantitative sensory testRNS: Repetitive nerve stimulationSEP: Somatosensory evoked potentialSFEMG: Single-fiber electromyographySIG: Special interest groupSSR: Sympathetic skin responseTOS: Thoracic outlet syndromeTST: Thermoregulatory sweat testTTS: Tarsal tunnel syndromeUS: Ultrasound

5

Tips & Tools for the Meeting

PICTURES: AANEM takes photos during the meeting for use in future publications. Personal cameras and video equipment are not allowed in the annual meeting sessions or exhibit hall.

INSTAGRAM: Follow us on AANEMorg, share your photos from New Orleans using the #AANEM hashtag so we can like and share them!

FACEBOOK: Like our Facebook page to see updates from themeeting.

ATTIRE: AANEM encourages all attendees to dress casually and comfortably for the meeting.

WI-FI: You will be able to use your smartphone, tablet, and/or laptop throughout the event space thanks to complimentaryWi-Fi.

EMAIL: AANEM will send timely email announcements throughout the meeting. If you are not receiving them, stop by registration to update your email.

TWITTER: Follow us [email protected]. Share your meeting experience with others using the #AANEMhashtag.

WEBSITE: Visit the AANEM website for updated meeting information at aanem.org/meeting.

MOBILE APP: Download the AANEM mobile App for updated meeting info.

Education Products Display Wednesday – Thursday 8:00 AM – 6:00 PM Friday 8:00 AM – 4:00 PM Saturday 8:00 – 10:00 AM

AANEM books, self-assessment exams, and coursebooks as well as the Nandedkar Productions EMG on DVD series are available for purchase at the Education Products Display.

Take advantage of this time to peruse your favorite educational resources, ask questions, and chat with AANEM staff!

Come see the new, interactive EMG Recruitment Trainer, 2016 Online Self-Assessment Exams and the new Ulnar Neuropathy PIP demonstrated in the Education Products Display. Visit the AANEM website www.aanem.org/Education to view the latest 2016 releases of Case Studies, Journal Reviews, and Ethics Vignettes offering member free CME.

AANEM educational resources focus on prevention, diagnosis, treatment, research, and ethical issues related to NM, EDX, and MSK medicine. AANEM offers products that meet ABPN and ABPMR MOC requirements for both performance improvement and self-assessment CME.

Tuesday: 6:00 – 9:00 PMWednesday: 7:00 AM – 6:00 PMThursday: 8:00 AM – 6:00 PMFriday: 8:00 AM – 4:00 PMSaturday: 8:00 AM – 10:00 AM

Office phone: (504) 586 - 4664

Cancellation/Refund PolicyOn-site cancellations of individual sessions with limited enrollment will

be refunded at 50% of purchase price. The ticket must be returned to the registration desk to receive a refund.

PaymentAll fees must be paid in US dollars. Full payment by cash, check or credit is required. To receive member rates, your 2016 membership dues must be current. If they are not, nonmember meeting rates will be charged.

Registration Hours:

Resident & Fellow Rush Tickets

Tickets that are still available for sessions 15 minutes before they begin can be picked up by residents and fellows for free on a first-come,

first-served basis at the registration desk.

ADM

INON

E

001237679

ADM

INON

E

001237679

OPEN

6

Speaker Ready RoomAll faculty and speakers are asked to visit the Speaker Ready Room, Belle Chasse located on the third floor of the Hilton New Orleans Riverside, prior to your presentations. You may utilize the Speaker Ready Room during the meeting to make changes to your presentation or to load your presentation for AV staff to transfer to your session’s room. Please load presentations at least one hour prior to the beginning of your session to allow time for AV

staff to transfer your presentation. If you would prefer to bring your presentation to the session room on your own via flash drive, you may do so as well. The hours for the Speaker Ready Room are:

Tuesday, Sept. 13: 6:00 PM - 8:00 PMWednesday, Sept. 14: 7:00 AM - 4:00 PMThursday, Sept. 15: 7:00 AM - 4:00 PMFriday, Sept. 16: 7:00 AM - 4:00 PMSaturday, Sept. 17: 7:00 - 11:30 AM

Wednesday, Sept. 14

Morning BreakMark A. Ferrante, MD -

EMG: What We Measure and What it Means

Mary J. Russo, CNCT, R.NCS.T- Essentials of Nerve Conduction Studies

Afternoon BreakSanjeev Nandedkar, MD -

DVD: Sensory NCS: Clinical Studies and Signals

Channarayapatna R. Sridhara, MD - DVD: Uncommon NCS

Lawrence R. Robinson, MD - Buschbacher’s Manual of NCS & DVD: EDX Evaluation of CTS

Thursday, Sept. 15

Morning BreakJeffrey A. Strakowski, MD -

Introduction to Musculoskeletal Ultrasound: Getting Started and Ultrasound Evaluation of Focal Neuropathies

Devon I. Rubin, MD - Clinical Neurophysiology, 4th Edition, EMG Recruitment Trainer and Waveform Trainer

Faye Chiou-Tan, MD - EMG Secrets (DVD): Repetitive Nerve Stimulation

Katharine E. Alter, MD - Ultrasound-Guided Chemodenervation Procedures: Text and Atlas

Afternoon BreakShin Oh, MD -

Principles of Clinical Electromyography Case Studies

John C. Kincaid, MD -DVD: Basic Nerve Conduction Studies

Paul E. Barkhaus, MD - DVD: Electronic Myoanatomic Atlas for Clinical EMG

David R. Del Toro, MD - DVD: EDX Evaluation of the Foot

Friday, Sept. 16

Morning BreakJun Kimura, MD –

Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice

Peter D. Donofrio, MD - Textbook of Peripheral Neuropathy

Michael S. Cartwright, MD, and Francis O. Walker, MD -

Neuromuscular Ultrasound

Afternoon BreakWilliam W. Campbell, MD -

Essentials of Electrodiagnostic Medicine (DVD): EDX Evaluation of Ulnar Neuropathy

Donald B. Sanders, MD - Single Fiber EMG book and DVD

Michael T. Andary, MD - DVD: EDX Evaluation of CTS

Meet The Author

Schedules subject to change. Refer to mobile App for updates.

Exhibit Hall HoursGrand Ballroom C & D, Level 1Wednesday 5:30 - 7:00 PMThursday 9:00 AM - 4:00 PMFriday 9:00 AM - 4:00 PM

Thursday, 10:15 AM$100 Amazon Gift Card

Thursday, 3:30 PM $100 Amazon Gift Card

Friday, 10:15 AM$100 Amazon Gift Card

Friday, 3:30 PM$250 Garmin Vivoactive

Smart Watch

Visit ALL exhibitors listed on your Exhibit Hall Passport (Page 9) and get your passport stamped. Once all stamps have been received, complete your entry information and deposit the completed passport into the drop-box located near the entrance of the Exhibit Hall. Only one game card per registered attendee will be accepted as a valid entry. All drawings will take place in the Exhibit Hall and winners must be present to win.

EXHIBIT HALL PASSPORT

7

How to Claim CME/CEU Credit:All CME/CEU recording for the Annual Meeting must be completed online. Record your hours viawww.aanem.org/CMEform or the new meeting app after each session or do it all at once after the meeting!

Complete the CME/CEU Recording Form for all hours of participation in general sessions (i.e. the Plenary, Ask the Experts, courses, symposia, poster sessions etc.). Please note:• Credit for workshops is recorded automatically, all other credit must be recorded manually.• Do not claim credit for self-assessment sessions, if participating in an Annual Meeting Self-Assessment Course.

CME for the full self-assessment activity will be awarded with successful completion of the post-test.• The CME/CEU Recording Form may be modified until December 31, 2016. Credit submitted after this date will

incur a $25 late fee and will not be reported to ABPN or ABPMR.

Meeting Objectives and Notes:The 2016 annual meeting will focus on improving patient care, medical knowledge, interpersonal communication, professionalism, and systems-based practices in the following areas: neuropathies, updates in NM disorders including CIPD, emerging gene therapies for NM disease, hyperexcitable membranes, iatrogenic and autoimmune disorders, EDX for focal neuropathies, genetics, infection, stem cell therapy, US and MSK disorders.

After attending this activity, attendees will: • Enhance their ability to obtain a comprehensive patient history and examination; improve their ability to develop a differential diagnosis and direct appropriate diagnostic work-ups; and assess rehabilitation potential for patients with NM and MSK diseases. (Patient care) • Develop technical skills necessary to perform neurologic, EDX, and rehabilitative procedures; identify and describe important EDX, biopsy, genetic, radiological, and US findings; develop awareness about the side effects of drug therapies and their management; and understand updated information on the genetic basis of NM disorders and their treatment. (Medical knowledge, Practice based learning)• Improve ability to communicate with and educate patients, families, and members of the healthcare team; develop awareness of ethical and biomedical legal issues related to patient care; enhance awareness of patient confidentiality issues as they relate to patient care; demonstrate professionalism in clinical, research, and academic practice; and demonstrate skills in end-of-life care and withdrawal of support. (Interpersonal communication skills, Professionalism)• Develop awareness of cost effectiveness of diagnostic studies and treatments

and resource limitations in health care; identify and access supportive healthcare services and mechanisms that improve patient care and patient quality of life. (Systems-based practice)

Accreditation Statement The AANEM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation StatementThe AANEM designates this live activity for a maximum of 25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Royal College of Physicians & Surgeons of Canada Activities held outside of Canada developed by a university, academy, specialty society or other physician organization can be recorded as accredited group learning activities under Section 1 of the Royal College of Physicians and Surgeons of Canada’s Maintenance of Certification (MOC) Program. The AANEM is a physician organization accredited by the ACCME.

American Society of Electroneurodiagnostic Technologists ASET – The Neurodiagnostic Society has granted ASET Continuing Education Units [ASET – CEUs] for this program. Such crediting, however, should not be construed by program participants as an endorsement of any type of instruments or supplies mentioned or involved in these presentations.

Password: Grifols2016

FreeWiFi compliments of

MOBILE APP:Download the AANEM mobile App for updated meeting info.

italksHave something to share? Lead an

informal conversation with your peers on hot topics, offer your insights, or

lead a themed discussion at an iTalk.

To host a discussion, sign up by the designated iTalk area in the Chemin

Royal hallway.

Dine AroundsSign up to join a Dine Around group for

lunch on Thursday or Friday.

Choose from 6 different locations (up to 10 people each). AANEM board members will join each group (each

participant is responsible for their own lunch expense.)

Sign-up sheets are posted in the Chemin Royal hallway.

OrientationMeet & Greetfor First Timers

Tuesday, September 13, 20165:00 - 6:00 PM

If this is your first time attending an AANEM Annual Meeting, join

us for a meeting overview, tour of the facility, and “can’t miss” recommendations on sessions.

Meeting on 3rd level, Melrose Room

Sponsored by:

8

Plenary #4: Saturday, Sept. 17 Professor of Medicine and Gregory Mario and Jeremy Mario Professor of Business AdministrationAssociate Director, Duke Clinical Research Institute, Duke University, Durham, NCLecture Topic: The Economics of

Specialty PharmaceuticalsIn this lecture, Dr. Schulman will focus on an understanding of the economic impact of speciality pharmaceuticals on insurance premiums, and suggest the potential for alternative strategies for drug development to address cost considerations in the development of these new therapeutic products.

Plenary #2: Thursday, Sept. 15Neurology Professor, University of Virginia; Vice Chair of Clinical Affairs, Neurology Department, University of Virginia; Endowed Chair, Harrison Distinguished Teaching Professor in Neurology, Charlottesville, VA

Lecture Topic: Measurement of NMDs in the Clinic SettingIn this lecture, Dr. Burns will discuss focus on measuring disease status in everyday clinic and patient-reported measures for treatable NM disorders.Edward H. Lambert Lecture: Initiated at the 1976 meeting to honor AANEM founding member, Dr. Edward H. Lambert, for his pioneering work in clinical electrodiagnostic medicine and neuromuscular diseases. In 2015, Vanda Lennon gifted the Foundation Funds in continued support.

2016 Plenary Speakers

Kevin A. Schulman, MD, MBA

Plenary #1: Wednesday, Sept. 14Assistant Professor, Dept. of Neurology, Division of Neuromuscular DiseasesBeth Israel Deaconess Medical Center/Harvard Medical School, Boston, MALecture Topic: Evidence-Based Guidelines vs. Consensus

Statements: Comrades or Rivals?In this lecture, Dr. Narayanaswami will discuss the two methods of developing

practice recommendations, evidence-based and formal consensus based, and their relative advantages and disadvantages.

Plenary #2: Thursday, Sept. 15 Professor and Vice Chair, Department of Physical Medicine & Rehabilitation, UC Irvine School of Medicine, Irvine, CALecture Topic: Innovative Technology in NMDs: Towards Improving

Upper Extremity FunctionIn this lecture, Dr. Han will provide

a brief overview of some basic outcome measures and assessment concepts relevant for NMDs; focus on upper extremity functional assessment using motion sensor technology and the latest scalable technologies for use in clinical and research settings; research and findings with implications for various NM disorders; research applications in clinical trials; and some of the future innovative technology intervention developments including robotics and exoskeletons.Stuart Reiner Lecture: Begun in 1988 in recognition of Stuart Reiner’s contributions to the development of instrumentation.

Plenary #3: Friday, Sept. 16 Chief of Neurology, Massachusetts General Hospital; Julieanne Dorn Professor of Neurology, Harvard Medical School,Boston, MALecture Topic: Developing Multidisciplinary Clinics for NM

Care and Research In this lecture, Dr. Cudkowicz will discuss survival and quality of life improved for people with ALS followed at multidisciplinary clinics; insurance in United States currently not covering the cost of this high quality care; setting up multidisciplinary clinics: costs/value and making this the standard for complex neurological disorders and care, and the importance of foundations and philanthropy in supporting excellence in care.Richard K. Olney Lecture: Begun in 2006 with funds provided by Sanofi-Aventis, the Richard K. Olney Lecture was created to honor Dr. Olney’s contributions to the field of ALS research.

Plenary #3: Friday, Sept. 16Professor of Neurology, Pediatrics, and Neuroscience, The Ohio State University Wexner Medical Center,Columbus, OHLecture Topic: Emerging Gene Therapies in NMD: SMA as Prototype

In this lecture, Dr. Kissel will provide a brief yet comprehensive update and state-of-the-art review of the genetic diagnosis and outlook for definitive gene-based therapies in these challenging disorders. Attention will also focus on future technologies (e.g. CRISPR/Cas9) showing promise to treat or even cure other NM conditions.

John T. Kissel, MD

Insight and Innovation inNeuromuscular Medicine

Pushpa Narayanaswami,MBBS, DM, FAAN

Ted M. Burns, MD

Jay J. Han, MD

Merit E. Cudkowicz, MD

9

Exhibit Hall Passport

Thursday, 10:15 AM$100 Amazon Gift Card

Thursday, 3:30 PM $100 Amazon Gift Card

Friday, 10:15 AM$100 Amazon Gift Card

Friday, 3:30 PM$250 Garmin Vivoactive

Smart Watch

Visit ALL exhibitors listed on your Exhibit Hall Passport and get your passport stamped. Once all stamps have been received, complete your entry information and deposit the completed passport into the drop-box located near the entrance of the Exhibit Hall. Only one game card per registered attendee will be accepted as a valid entry. All drawings will take place in the Exhibit Hall and winners must be present to win.

Prize Drawings in Exhibit Hall:

Booth 313 Booth 409 Booth 108

Booth 210 Booth 217

Booth 110 Booth 215 Booth 102

Registered Attendee Name:

Badge Number (located in the lower right-hand corner of your badge):

Email: Cell Phone for Text Notifications:

PASSPORT

10

AANEM Sponsored ToursCooking Gumbo Ya Ya | Demonstration Class

Wednesday, Sept. 14 10:00 AM - 12:00 PM OR Friday, Sept. 162:00 - 4:00 PM$50 per person (52 people max)

Learn to prepare the distinctive dishes for which New Orleans is

famous at the New Orleans School of Cooking.

Garden District Grandeur and Shopping on Magazine Street

Wednesday, Sept. 142:00 - 4:30 PM$60 per person (100 people max)

Tour the grand Garden District, followed by a visit to Magazine Street, the current hot spot in New Orleans.

Antiquing at M.S. Rau

Thursday, Sept. 15 10:00 AM - 12:00 PM$40 per person (43 people max)

M.S. Rau Antiques has been a French Quarter landmark for more than 100 years.

Their 25,000-square-foot showroom literally overflows with remarkable Collections of fine art, exquisite jewelry, and exceptional 18th and 19th - century antiques.

Garden District and Mansion Tour

Thursday, Sept. 151:00 - 3:00 PM$75 per person (70 people max)

Tour the the grand Garden District, then enjoy the southern hospitality of New Orleans at the Elms

Mansion. Built in 1869, The Elms Mansion takes over nearly an entire block on oak-lined St. Charles Avenue.

Jazz Club Crawl

Thursday, Sept. 157:15 - 10:15 PM$125 per person (25 people max)

Visit two of New Orleans’ oldest Jazz clubs. Enjoy an intimate, acoustic New Orleans jazz concert at Presentation Hall followed by a visit to Bourbon Street’s oldest live jazz club, Maison Bourbon.

Cajun Pride Swamp Tour

Friday, Sept. 168:30 AM - 12:30 PM$65 per person (200 people max)

Cajun Pride’s privately owned bayou offers an authentic and intimate view of the swamp

and its inhabitants.

Down-Home Airboat Adventure

Saturday, Sept. 178:45 AM - 12:15 PM$110 per person (125 people max)

Airboats zip you through narrow canals lined with

moss-covered Cyprus trees to wide-open grassy marshes crawling with wildlife.

Social EventBroussard’s French Quarter Fusion Dining Experience

Saturday Sept. 17 5:15 - 7:30 PM$125 per person*

Located right in the heart of New Orleans’ Vieux Carre, or French Quarter, Broussard’s merges a mix of classic food, old architecture,w and tradition to achieve an experience that you’ll always remember. *Price includes hors d’oeuvres and drinks in the private courtyard before enjoying dinner. Transportation not included to allow attendees to enjoy the French Quarter before and after dinner.

To register for open tour, stop at the registration desk. All prices include round-trip ground transportation, admission charges, taxes, and gratuities. Comfortable shoes and clothing are recommended. While every effort will be made to accommodate tour requests, minimum numbers must be met for a tour to operate. In the event that a tour minimum is not met and a tour must be canceled, AANEM will refund the full payment.

11

Annual Meeting Self-Assessment Courses:The four courses indicated below have been designated to offer Part II MOC Self-Assessment (SA) credit and are eligible for up to 9 SA CME. Successful Completion of the pre- and post-test and course attendance is mandatory to conclude the full self-assessment cycle and receive SA credit towards MOC. Only one SA Course per day may be attended. CME must not be recorded separately for the course you attend; this CME count will automatically be recorded in the total activity CME once the post-test is successfully completed.

AANEM will report successful completion of each SA Course activity to ABPN and ABPMR.

Wednesday, Sept. 14, 8:00 AM – 12:00 PMNM Topics in Sports MedicineThe Approach to the Pediatric Patient With NM Disorders

Thursday, Sept. 15, 1:30 – 5:30 PMEDX and Ultrasound of Focal NeuropathiesPrinciples of NCS and Needle EMG

ABPN & ABPMR Approval: The American Board of Psychiatry and Neurology (ABPN) and The American Board of Physical Medicine and Rehabilitation (ABPMR) have reviewed the AANEM Annual Meeting Self-Assessment Courses and have approved this program as part of a comprehensive self-assessment program, which is mandated by the American Board of Medical Specialties as a necessary component of maintenance of certification.

Accreditation Statement: The AANEM is accredited by the ACCME to provide continuing medical education for physicians.

CME Designation Statement: The AANEM designates this live activity for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Information: Dr. Shetty is on the GE NFL medical advisory board and has 3 research grants (GE, Abbott, Chembio). Dr. Tilton is an investigator and consultant with Ipsen Pharmaceuticals. All conflicts of interest have been resolved in accordance with ACCME Standards for Commercial Support SM. All other speakers for the Annual Meeting Self-Assessment Courses had nothing to disclose. This activity was planned by the AANEM Program Committee. For specific disclosure information on planners, please refer to the Disclosure Appendix at the back of the Meeting Guide.

12

RIVERFRONT STREETCAR DEPOT

FRONTENTRANCE

POYD

RAS

STRE

ET

CONVENTION CENTER BLVD. TO CONVENTION CENTER

SIDE DRIVE

WORLD TRADE CENTERPARKING GARAGE

TO MAINLOBBY

CONCIERGE GIFTSHOP

1ST FLOORREGISTRATION COUNTERS

LE CROISSANTBURGUNDY

GRAND BALLROOM

CHEMIN ROYALE

GRAND SALON

A B C D

3 6 9 12 15 18 21

1 4 7 10 13 16 19 22

2 5 8 11 14 17 20 23

24

First Level

GUESTROOM

ELEVATORS

N S

Second LevelTO RIVERSIDE BUILDING

FRO

NT

DESK

ACCESSORIESTO DESIRE

BELLMAN’SSTAND

WHEELCHAIR ACCESSTO RIVERSIDE BUILDING

ATRIUMSPACE

EXECUTIVEOFFICES MARLBOROUGH

PRINCEOF WALES

WORKROOM

ELEVATORS TO 1STAND 3RD FLOORS

AND PARKINGGARAGE (5TH LEVEL)

AB

A B C

HILTON EXHIBITION CENTER

ELEVATORS TO PARKINGLEVELS 3, 4, 5/HEALTH CLUB

& BEAUTY SALON

LUGGAGESTORAGE

AREA

GUEST ROOM ELEVATORS

CHEQUERS

CAMBRIDGEEGLINTONWINTON

BUSINESSCENTER

Hilton New Orleans Riverside Maps

13

POOL

FOUNTAINROOM

JEFFERSONBALLROOM

EVENTSERVICES

Third Level

SALES/MARKETINGREVENUE MANAGEMENT

CATERING/EVENTSOFFICES

ATRIUM

NORWICHDURHAM

WARWICK

GUEST ROOM

ELEVATORS

ASCOT

NEWBERRY

WINDSOR

JASPERW

OO

D

MA

GN

OLIA

ROSED

OW

N

OA

K ALLEY

ELMW

OO

D

BELLE CHA

SSE MELROSE

VERSAILLESBALLROOM

NAPOLEON BALLROOM

COURTASSEMBLY

ELEVATORS TO 1st & 2nd FLOORS AND PARKING GARAGE (5TH LEVEL)

To Riverside Building

REGISTRATION COUNTERSN S

TRAFALGAR

WOMENMEN

ESCALATOR

CRESCENTCITY

MARKETPLACE

FOUNTAINLOBBY

REG

ISTR

ATIO

N

REGISTRATION

BUILDING2

MISSISSIPPI RIVER

TO GUEST ROOMS QUARTERDECKA

QUARTERDECKB

QUARTERDECKC

LEEWARD

KABACOFF

PELICAN

COMPASS

STEERING

BRIDGE

PORT

STARBOARD

RIVER

CHARTA

CHARTB

CHARTC

WINDWARD

RiversideComplex

BUILDING3

TO GUEST ROOMS

14

Meeting Sessions

NM Topics in Sports MedicineMulti-Level • 3 CME/CEU • 8:00 AM - 12:00 PMGrand Ballroom B

(1) Design EDX testing to most effectively evaluate peripheral nerve injury in athletes, (2) utilize NM and MSK US for diagnosis and treatment of sports-related nerve entrapments, (3) diagnose and treat sports-related shoulder and brachial plexus injuries, and (4) learn of the potential benefits and limitations of sports participation in patients with pre-existing NM disorders. 8:00 AM Introduction Peter Q. Warinner, MD8:05 AM Design EDX Testing to Most Effectively Evaluate Peripheral Nerve Injury in Athletes Peter Q. Warinner, MD8:25 AM Benefits, Limitations, and Strategies of SportsParticipation in Patients With Pre-Existing NM Disorders Peter Q. Warinner, MD8:45 AM Utilizing NM and MSK US for Diagnosis and Treatment of Sports-Related Nerve Entrapments Joanne P. Borg-Stein, MD9:30 AM Break 10:30 AM NM Diagnosis of Shoulder Pain and WeaknessChiawen L. Liang, MD 11:00 AM Spinal Cord Injuries From Sports Teena Shetty, MD11:45 AM Discussion and Q & A

The Approach to the Pediatric Patient With NM DisordersMulti-Level • 3 CME/CEU • 8:00 AM - 12:00 PMGrand Ballroom A

(1) Discuss the clinical characteristic and diagnostic approach to the pediatric patient with NM disorders, (2) develop a systematic approach to the role of electrophysiology and adjunctive techniques in the pediatric patient, and (3) discuss the latest updates in diagnostics and treatments applicable to the pediatric patient.

8:00 AM Introduction Ann H. Tilton, MD 8:10 AM The Floppy InfantNancy L. Kuntz, MD

8:50 AM Progressive Weakness in the Child Seth J. Perlman, MD

9:30 AM Break

10:30 AM Diagnostic Techniques Including Novel and Painless Craig Zaidman, MD 11:10 AM The Rehabilitation of the Child with NM Disorders Katharine E. Alter, MD

11:50 AM Discussion and Q & A

Challenging NM and EDX CasesMulti-Level • 3 CME/CEU • 8:00 AM - 12:00 PMRosedown

Acquire skills to apply and refine the process of diagnostic formulation in clinical neurophysiology and improve patient care. This symposium relies on attendees to provide challenging cases.

8:00 AM Bashar Katirji, MD

W01M1 ChemodenervationAdvanced • 3 CME/CEU • 8:00 AM - 12:00 PM

Observe and discuss patient treatment and EDX techniques involved in administering botulinum toxin for cervical, facial, oromandibular, and limb dystonia, as well as upper and lower limb spasticity. An initial didactic session will discuss key issues regarding dystonia and spasticity, therapeutic use of the available botulinum toxins, electrophysiologic characteristics of dystonic firing patterns, chemodenervation techniques, and relevant anatomy. Then rotate through four demonstration sessions that will focus on facial dystonia, cervical dystonia, limb/oromandibular dystonia, and upper and lower limb spasticity. Acquire skills to treat patients with dystonia and spasticity using chemodenervating agents.

8:00 AM Janice M. Massey, MD, Joshua P. Alpers, MD, Atul T. Patel, MD, Zaeem A. Siddiqui, MD, PhD

W02A Autonomic Testing Using EMG EquipmentBasic • 1.5 CME/CEU • 8:00 - 9:30 AM

Acquire the skills to (1) perform the two quantitative tests for autonomic function, SSR and heartrate variability studies, and (2) apply this technique into standard EDX practice where appropriate.

8:00 AM Benn E. Smith, MD

*Workshops are for physicians only, unless indicated that it is also open to technologists

Sept. 14thWednesday Registration: 7:00 AM - 6:00 PMPosters: 8:00 AM - 6:00 PMExhibit Hall: 5:30 PM - 7:00 PMSpeaker Ready Room: 7:00 AM - 4:00 PM

Courses

Symposium

Workshops*-Morning*

MN

N

MNE AP

E

NE

MGFA Session 8:00 AM -12:45 PMSee info on page 20

15

W18A NM USBasic • 1.5 CME/CEU • 8:00 - 9:30 AM

(1) Obtain images with transverse and longitudinal transducer positions, (2) describe how to manipulate basic US instrumentation to include focal depth, Doppler flow, and transducer frequency, (3) describe how muscle, nerve, and tendon appear with US, and (4) discuss the principle of anisotropy.

8:00 AM Francis O. Walker, MD W20A Office-Based Injection ProceduresBasic • 1.5 CME/CEU • 8:00 - 9:30 AM

(1) Describe the principles underlying the safe and effective performance of office-based procedures; (2) identify contraindications to select office-based injection procedures, identify appropriate patients, prepare and instruct them on what to expect during and after a given procedure; (3) describe and demonstrate commonly performed office-based injection procedures, including trigger-point injections, shoulder and knee injections, bursal injections, carpal tunnel injections, and botulinum toxin injections for migraine and cervical dystonia; and (4) become aware of the complications that may result from office-based injection procedures, how to minimize the chance of complications, and manage complications if they arise.

8:00 AM Michael D. Stubblefield, MD

W33A-B You Make the Call: An Interactive Approach to the Skills of EMG Waveform RecognitionBasic • 3.5 CME/CEU • 8:00 AM - 12:00 PM

(1) Identify the patterns of firing of different types of EMG waveforms, (2) identify the characteristics of a variety of normal and abnormal spontaneous waveforms, (3) recognize normal and abnormal patterns of recruitment of MUAPs, and (4) recognize and understand the significance of the changes in morphology of MUAPs in diseases. Includes audience participation and videos of EMG waveforms.

8:00 AM Devon I. Rubin, MD

W55A Myopathies: EDX ApproachBasic • 1.5 CME/CEU • 8:00 - 9:30 AM

(1) Discuss and interpret myopathic features on EDX studies including distinctive features, (2) explain the EDX features that differentiate myopathic from neuropathic processes,(3) determine muscle selection criteria during EMG studies for myopathies, and (4) explain the different types of myopathies and learn how EDX studies and other testing aids in making the diagnosis.8:00 AM Jafar Kafaie, MD, PhD

W57A US MSK Lower ExtremityAdvanced • 1.5 CME/CEU • 8:00 - 9:30 AM

(1) Explain which transducer frequencies are typically used for imaging lower extremity joints in adults, (2) override a differential diagnosis of lower extremity joint pain, (3) identify key landmarks in lower extremity joints using US, and (4) describe the pathologic changes of tendon rupture, tear, and inflammation.

8:00 AM Jeffrey A. Strakowski, MD

W58A US Upper Extremity Nerves and PlexusAdvanced • 1.5 CME/CEU • 8:00 - 9:30 AM

(1) Explain the optimal transducer frequency for imaging upper extremity nerves, (2) identify the median nerve at the wrist, ulnar nerve at the elbow, and brachial plexus using US, (3) describe normal median nerve mobility and the appearance of ulnar nerve dislocation on real-time US, and (4) list the findings of nerve entrapment as may be seen on US and findings in structures other than nerve that may be relevant.

8:00 AM Vanessa Baute, MD

W60A US MSK Upper ExtremityAdvanced • 1.5 CME/CEU • 8:00 - 9:30 AM

(1) Explain which transducer frequencies are optimal for imaging upper extremity joints in adults, (2) provide a differential diagnosis of joint pain in the upper extremity, (3) identify key landmarks in upper extremity joints using US, and (4) describe the pathologic changes of tendon rupture, tear, and inflammation.

8:00 AM John W. Norbury, MD W62W1 NCS WorkshopMulti-Level • 3.5 CME/CEU • 8:00 am - 12:00 pm

Taught by technologist and physician teams with emphasis on hands-on learning and actual case presentations, this half-day session will (1) exhibit how to perform basic NCSs in the upper extremity and lower extremity, (2) show how to perform repetitive stimulation, (3) describe common pitfalls of NCSs,(4) identify the most common mononeuropathies in the upper and lower extremity, and (5) explain how to use this knowledge to work through a case and come up with the correct diagnosis.

8:00 AM Ann A. Little, MD; Teresa Spiegelberg, CNCT, R.NCS.T, R.EEG.T, B.S., James W. Teener, MD

E ElectrodiagnosticN NeuromuscularM MusculoskeletalWednesday Academic/PracticeRelatedAP

Also open to Technologists Also open to Technologists

Also open to Technologists


MN

MN

E

E

M

N

M

E


16

W64AB Resident and Fellow Boot CampBasic • 8:00 AM - 12:00 PM

Designed for residents and fellows, participants will

(1) demonstrate less commonly used NCSs, (2) review pitfalls associated with common NCSs, and (3) identify which tests (NCS and EMG) constitute the optimal EDX evaluation of the foot as well as how to perform needle EMG in the foot and interpretation of these findings.

8:00 AM Lawrence R. Robinson, MD

Therapeutic Nerve HydrodissectionBasic/Advanced • 9:45 - 10:15 AMGrand Ballroom B

Nerve hydrodissection is a technique used to treat focal neuropathies due to compression, entrapment or injury. This is a minimally invasive nonsurgical procedure that uses US technology to alleviate symptoms of compressed nerve disorders in this short overview by renowned US expert Jeff Strakowski, MD

11:45 AM Jeffrey A. Strakowski, MD

W02B Autonomic Testing Using EMG EquipmentBasic • 1.5 CME/CEU • 10:30 am - 12:00 pm

10:30 Benn E. Smith, MDSee description on page 14, (W02A)

W18B NM USBasic • 1.5 CME/CEU • 10:30 am - 12:00 pm

10:30 Francis O. Walker, MDSee description on page 15, (W18A) W20B Office-Based Injection ProceduresBasic • 1.5 CME/CEU • 10:30 am - 12:00 pm

10:30 Michael D. Stubblefield, MDSee description on page 15, (W20A)

W22B Skin Biopsy Technique & ApplicationsBasic • 1.5 CME/CEU • 10:30 am - 12:00 pm

(1) Review the development of skin biopsy as a clinical technique, (2) review its current applications and limitations in clinical practice, and (3) discuss the technique involved in obtaining skin specimens to increase providers’ comfort level in performing this billable procedure in their own office.

10:30 AM David W. Polston, MD W55B Myopathies: EDX ApproachBasic • 1.5 CME/CEU • 10:30 AM - 12:00 PM

10:30 Jafar Kafaie, MD, PhDSee description on page 15, (W55A)

W58B US Upper Extremity Nerves and PlexusAdvanced • 1.5 CME/CEU • 10:30 AM - 12:00 PM

10:30 AM Monika Krzesniak-Swinarska, MDSee description on page 15, (W58A)

W61B US Lower Extremity Nerves and MusclesAdvanced • 1.5 CME/CEU • 10:30 AM - 12:00 PM

(1) Explain optimal transducer frequencies for imaging lower extremity nerves, (2) identify the tibial nerve at the ankle and knee, the fibular nerve at the knee, and the sciatic and sural nerves using US, (3) describe the branching patterns of tibial, fibular, and sural nerves in the lower extremities, and (4) list expected findings of nerve entrapment as may be seen on US and findings in structures other than nerve that may be significant.

10:30 AM Steven J. Shook, MD

An Integrative Medicine Approach to Treating NM DiseaseAdvanced • 1.5 CME/CEU • 1:30 - 3:00 PMGrand Ballroom A

(1) Understand the role of integrative medicine in evaluating and managing patients with painful peripheral neuropathy, (2) learn the existing scientific theory behind and evidence for complementary therapies to treat neuropathic pain, (3) review the role of supplements in the treatment of muscle disease and muscular dystrophy, (4) discuss recent integrative modalities in ALS, and (5) apply integrative medicine principles and complementary therapies to your practice.

1:30 PM Introduction Vanessa Baute, MD

1:40 PM Concoctions, Compounds, and Cure-Alls: Supplements in Muscle Disease and ALSAlyson M. Hommel, MD

2:15 PM An Integrative Approach to Treating Neuropathic Pain Danielle L. Zelnik, MD 2:50 PM Discussion and Q & A

Symposiums



Informational Session

NE

MN

E

NE

MN

N

E

MN

M

MNE AP



Workshops

Sponsored by Natus Neurology

17

Controversies in ElectrodiagnosisAdvanced • 1.5 CME/CEU • 1:30 - 3:00 PMGrand Ballroom B

(1) Explain the controversies in the evaluation, diagnosis, and management options in piriformis syndrome and neurogenic TOS, (2) discuss whether the use of EDX studies are over or underutilized in these syndromes, and (3) determine if the addition of diagnostic US has added value in diagnosis of neurogenic TOS.

1:30 PM IntroductionMichael N. Horner, DO1:35 PM Piriformis Syndrome: There’s a Simple ExplanationSuzanne M. Manzi, MD

1:55 PM Piriformis Syndrome: There’s Always AnotherExplanationMichael T. Andary, MD, MS

2:15 PM Neurogenic TOS: Underdiagnosed ConditionBenjamin M. Sucher, DO

2:35 PM Neurogenic TOS: Overdiagnosed ConditionShawn J. Bird, MD

2:55 PM Panel Discussion and Q & A Updates in NM Transmission DisordersAdvanced • 1.5 CME/CEU • 1:30 - 3:00 PMRosedown

(1) Discuss current perspectives in the management of MG patients, (2) describe new immunosuppressant therapies and review thymectomy in the management of MG, (3) recognize the most common CMS phenotypes, (4) underscore the relevance of molecular diagnosis in regard to treatment of CMS, (5) discuss current strategies for evaluation and guidelines for management of LEMS and botulism, and (6) describe the role of 3,4 DAP for treatment disorders of NM transmission.

1:30 PM Introduction Vita G. Kesner, MD, PhD 1:35 PM Advances in the Management of Autoimmune Myasthenia Gravis Mazen M. Dimachkie, MD .2:00 PM Overview of CMS Margherita Milone, MD, PhD 2:25 PM Presynaptic Disorders: LEMSVita G. Kesner, MD, PhD

2:50 PM Discussion and Q & A

W08C EMG LaryngealAdvanced • 1.5 CME/CEU • 1:30 - 3:00 PM

Develop skills in the clinical and EDX evaluation of vocal cord dysfunction, including (1) perform specific EDX testing of the larynx and (2) discuss how to evaluate which tests to perform on patients presenting with hoarseness and laryngeal dysfunction.

1:30 PM Michael C. Munin, MD W09C EMG Muscle IDBasic • 1.5 CME/CEU • 1:30 - 3:00 PM

(1) Perform anatomic localization of common and unusual muscles, (2) identify methods of selective activation, and(3) apply these techniques when performing the needle EMG examination.

1:30 PM Daniel L. Menkes, MD W11C EMG and US RespiratoryAdvanced • 1.5 CME/CEU • 1:30 - 3:00 PM

Focus on EDX and US techniques that enable a more accurate diagnosis of NM respiratory failure, including (1) perform phrenic NCSs, (2) utilize techniques for safe needle EMG of the diaphragm (including US-assisted), (3) localize and perform needle EMG of chest wall muscles, which are helpful in the diagnosis of respiratory failure, and (4) utilize US for evaluating thickness and contractility of the diaphragm.

1:30 PM Andrea J. Boon, MD, Jeffrey A. Strommen, MD

W12C Short Segment NCSBasic • 1.5 CME/CEU • 1:30 - 3:00 PM

(1) Explain the sources of experimental error in NCS,(2) compute the trade off between experimental error and lesion detection, (3) discuss the difference between inching and short segment incremental studies (SSIS), (4) demonstrate across elbow ulnar nerve SSIS technique, and (5) show across wrist median nerve SSIS technique.

1:30 PM William W. Campbell, MD



Workshops-Afternoon

N

N

E

E

E

E

18

W16C MUP QuantitationAdvanced • 1.5 CME/CEU • 1:30 - 3:00 PM

Familiarize participants with qualitative analysis of MUP features in a clinical setting, including (1) measure amplitude, duration, and firing rate, and (2) perform different methods of analysis by manual, trigger/delay, and automated methods. Basic skills in needle electrode examination are assumed.

1:30 PM Paul E. Barkhaus, MD

W18C NM USBasic• 1.5 CME/CEU • 1:30 - 3:00 PM

1:30 Michael S. Cartwright, MDSee description on page 15, (W18A)

W20C Office-Based Injection ProceduresBasic• 1.5 CME/CEU • 1:30 - 3:00 PM

1:30 Michael D. Stubblefield, MDSee description on page15, (W20A) W22C Skin Biopsy Technique & ApplicationsBasic • 1.5 CME/CEU • 1:30 - 3:00 PM

(1) Review the development of skin biopsy as a clinical technique, (2) review its current applications and limitations in clinical practice, and (3) discuss the technique involved in obtaining skin specimens to increase providers’ comfort level in performing this billable procedure in their own office.

1:30 PM David W. Polston, MD

W27C Repetitive Nerve StimulationBasic • 1.5 CME/CEU • 1:30 - 3:00 PM

(1) Perform RNS to shoulder, upper arm, hand, and facial muscles, and (2) discuss sequential examination for detecting NM transmission defects, such as artifacts.

1:30 PM Vettaikorumakankav Vedanarayanan, MD, FRCPC

W38C Integrating EMGs and US in Sports InjuriesBasic • 1.5 CME/CEU • 1:30 - 3:00 PM

(1) Describe the symptoms and expected physical exam for an injured athlete with a sprained ankle and a peroneal nerve

stretch injury, (2) list the neurodiagnostic findings expected in a pitcher with neurogenic TOS, and (3) cite the differential diagnosis in a gymnast with pain and weakness in her right shoulder.

1:30 PM Jeffrey A. Strakowski, MD W46C Paraspinal Mapping and the Evaluation of Lumbosacral Plexopathy/RadiculopathyBasic • 1.5 CME/CEU • 1:30 - 3:00 PM

(1) Establish a clinical and EDX approach to disorders affecting the lumbosacral roots and plexus, and (2) identify and distinguish findings between lumbar radiculopathies versus disorders affecting the lumbosacral plexus.

1:30 PM Andrew J. Haig, MD

W55C Myopathies: EDX ApproachBasic • 1.5 CME/CEU • 1:30 - 3:00 PM

1:30 Jafar Kafaie, MD, PhDSee description on page 15, (W55A)

W59C US Guidance for NeurotoxinsAdvanced • 1.5 CME/CEU • 1:30 - 3:00 PM

(1) Discuss the pros and cons of using in-plane and out-of-plane US views to guide needle placement, (2) compare and contrast the use of EMG needle guidance, nerve stimulation, and US for identifying neurotoxin targets in patients, (3) identify common targets for needle-guided injections using US, and (4) list the technical challenges of using US for needle guidance.

1:30 PM Katharine E. Alter, MD

W61C US Lower Extremity Nerves and MusclesAdvanced • 1.5 CME/CEU • 1:30 pm - 3:00 pm

1:30 Steven J. Shook, MDSee description on page 16, (W61B)




E

MN

MN

N

E

E M

E M

E

N

N


PNS Session 1:30 -3:00 PMSee info on page 20

19

What is MACRA?Multi-Level • 3:00 pm - 4:00 pmGrand Ballroom A

What is MACRA? What is the Quality Payment Program? How will it affect your practice and reimbursement? The AANEM Policy Department will be available for an informal Q&A session to field any questions or concerns you have on the complete overhaul of Medicare reimbursement coming in 2017 under MACRA.

3:00 PM Millie Suk, JD, MPP Carrie Winter, RHIA

Plenary 1 - Insight and Innovation in NM MedicineBasic/Advanced • 1.5 CME/CEU • 4:00 pm - 5:30 pmGrand Ballroom A & B

4:00 PM IntroductionWilliam S. Pease, MD

4:05 PM President’s Address Vern C. Juel, MD

4:25 PM Introduction Vern C. Juel, MD 4:30 PM Evidence Based Guidelines vs. Consensus Guidance Statements: Comrades or Foes?Pushpa Narayanaswami, MBBS, DM, FAAN 5:10 PM Awards: Best Abstract, Runner Up and GolsethVern C. Juel, MD 5:25 PM ClosingVern C. Juel, MD

5


Plenary

President’s ReceptionWednesday • 5:30 - 7:00 PM

Hilton New Orleans RiversideGrand Ballroom C & D

The President’s Reception is the official kickoff event of the meeting each year. Socialize with attendees and exhibitors

while enjoying snacks, wine, and refreshments.

Workshops Open to Technologists

NM US(W18A) pg. 15, (W18B) pg. 16 (W18C) pg. 18

US MSK Lower Extremity(W57A) pg. 15

US Upper Extremity Nerves and Plexus(W58A) pg. 15, (W58B) pg. 16

US MSK Upper Extremity(W60A) pg. 15

US Lower Extremity Nerves and Muscles(W61B) pg. 16, (W61C) pg. 18

NCS Workshop(W62W1) pg. 15

Repetitive Nerve Stimulation(W27C) pg. 18, (W27AS) pg. 33

Short Segment NCS(W12C) pg. 17NCS Pitfalls

(W21AS) pg. 33NCS Uncommon(W23AS) pg. 33

All other workshops open only to physicians

AP

MNE

Sponsored by:

20


MGFA SessionMulti-Level • 8:00 AM - 12:45 PMJefferson Ballroom

The MGFA Medical/Scientific Advisory Board presents a scientific session highlighting research in the area of MG and myasthenic disorders. This session is the premier annual event around the U.S. and world related to the pathogenesis, immunology, diagnosis, and treatment of MG and related disorders of the NM junction. Included in the program will be leaders in MG research from the scientific and clinical areas. 8:00 AM Introduction Edward Walsh, Michael K. Hehir, MD; Jeffrey T. Guptill, MD

8:15 AM Refractory MG, Outcome Measures and Clinical FeaturesRenato Mantegazza, MD

8:45 AM International Consensus Guidance for the Management of Myasthenia Gravis, Donald B. Sanders, MD

9:00 AM Micro-RNA and M-RNA Profiles Associated with Ectopic Germinal Center FormationManjistha Sengupta, PhD

9:15 AM B10 Deficiency in Myasthenia Gravis Is Not Associated with Defective T Cell SuppressionMelissa Russo, BS

9:30 AM B Cell Tolerance Defects and Abnormal B Cell Repertoire Formation in Mysthenia GravisKevin C. O’Connor, PhD

9:45 AM ALN-CCC5 An Investigational RNAI Therapeutic for the Treatment of Myasthenia Gravis: Interim Phase 1 Data in Healthy Volunteers and Efficacy in Pre-Clinical Animal Models of MGAnna Borodovsky, PhD

10:00 AM Break and Poster Session

11:15 AM Blinded Retrospective Analysis of Rituximab Treatment in Anti-Musk Myasthenia GravisMichael K. Hehir, MD

11:30 AM Beyond the Antibodies: Sera Metabolomic Biomarker Signatures Discriminate Myasthenic and Healthy CohortsZaeem A. Siddiqi, MD, PhD; Derrick Blackmore, BSc, PhD Cand.

11:45 AM Eculizumab Safety and Efficacy in Refractory Myasthenia Gravis: A Phase 3 Randomized, Double Blind, Placebo Controlled Multi Center StudyJames F. Howard, MD

12:00 PM Survivin Expression in B Cells of EAMG Rat Model is Suppressed with Survivin Peptide VaccineLinda L. Kusner, MD

12:15 PM A Phase 2 Trial of Rituximab in Myasthenia Gravis: Baseline DataRichard J. Nowak, MD, MS

12:30 PM Closing

Peripheral Nerve Society (PNS)

Biological Basis of Neuropathy: From Molecular

Causes to TherapyBasic/Advanced • 1:30 - 3:00 PM Jefferson Ballroom

The Peripheral Nerve Society is an international organization of physicians and scientists working together to develop and provide the best treatments for people who have peripheral nerve diseases. The PNS encompasses all aspects of the peripheral nervous system, both clinical and scientific, and ranges from electrophysiologic tools for diagnosis to molecular mechanisms of disease and nerve fiber regeneration. Participants will acquire skills to (1) summarize the latest research in genetic neuropathy, (2) understand mechanisms for recovering from neuropathy ; and 3) apply new treatments in neuropathy as they are developed.

1:30 PM The Genetic Causes of Neuropathy Steven S. Scherer, MD, PhD 1:55 PM Discussion and Q & A

2:00 PM Mechanisms for Recovering From NeuropathyAhmet Hoke, MD,PhD,FRCPC

2:25 PM Discussion and Q & A 2:30 PM Upcoming Treatments in Neuropathy David R. Cornblath, MD 2:55 PM Discussion and Q & A

N

21

Integrative Medicine in NM DiseaseMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 4

(1) Define integrative medicine and why it is important in NM disease, (2) review the evidence pertaining to neurologic complications of rapid weight loss and nutritional deficiency in common NM diseases including peripheral neuropathy and motor neuron disease, (3) define the role of exercise in NM diseases and how to incorporate as treatment, (4) discuss alternative and complementary therapies for CTS, and(5) review the current evidence for alternative medicine modalities to treat CTS including magnet therapy, yoga, and acupuncture.

8:00 AM Vanessa Baute, MD

Entrapment NeuropathiesMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 3

(1) Learn from Robinson how to use the Robinson Index for diagnosis of CTS, (2) review the best approaches for diagnosing ulnar neuropathy at the elbow, and (3) discuss how to formulate prognostic statements in focal neuropathies.

8:00 AM Lawrence R. Robinson, MD

Brachial Plexopathies Multi-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 6

(1) Review the anatomy of the brachial plexus, (2) review howthe sensory NCS are applied first to localize the lesion to a particular region of the brachial plexus (i.e., root vs trunk vs division vs cord vs terminal branch), (3) review how the motor NCS and the needle EMG study are used to further characterize the lesion (e.g., pathology, severity, rate of progression), and apply this approach to actual cases.

8:00 AM Mark A. Ferrante, MD

Peripheral NeuropathyMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 9

(1) Create a differential diagnosis of peripheral neuropathy and further divide the neuropathies into motor, sensory, and mixed types as well as into demyelinating and axon loss types (2) discuss an EDX approach to evaluating patients with diffuse polyneuropathies, and (3) discuss treatment options for neuropathies from immunosuppression to neuropathic pain management.8:00 AM Peter D. Donofrio, MD

Coding for EDX/NMDMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 12

(1) Explain the basics of EDX and NM CPT coding, (2) discuss basic ICD-10 coding concepts, documentation requirements and pertinent examples, and (3) how to appeal denials.

8:00 AM Carrie Winter, RHIA

Lower Back Pain Multi-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 13

(1) Provide an evidence-based approach to selecting medications to treat back pain, (2) explain the advantages and disadvantages of each of the common approaches to managing back pain, (3) discuss the nonpharmacologic strategies for dealing with back pain, and (4) outline the principles used to decide whether a topical preparation might be a good therapeutic choice for back pain.

8:00 AM Francis P. Lagattuta, MD

RadiculopathyMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 15

(1) Discuss the framework for assessing for radiculopathy, (2) explain the optimal examination for radiculopathy that minimizes pain and insures high diagnostic accuracy, and (3) list the limitations of needle EMG.

8:00 AM Timothy R. Dillingham, MD, MS MND and its MimicsMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 16

(1) Identify NM disorders that present with painless weakness and mimic MNDs, (2) distinguish the clinical features of various MNDs (e.g., ALS, monomelic amyotrophy, Kennedy’s disease) from one another, and (3) select and interpret appropriate EDX, laboratory, and imaging studies to properly diagnose patients with MNDs and their mimics.

8:00 AM Zachary Simmons, MD

Ask The Expert Sessions*

Sept. 15thThursday

N

N

NE

N

AP

N

E M

NE

*No breakfast provided at Ask the Experts Sessions.Seating is limited - come early to claim a seat.

Registration: 8:00 AM - 6:00 PMPosters: 8:00 AM - 7:30 PMExhibit Hall: 9:00 AM - 4:00 PMSpeaker Ready Room: 7:00 AM - 4:00 PM

22

How to Incorporate Genetic Testing into Practice Multi-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 18

Acquire skills to give an algorithmic approach to ordering genetic tests for patients with suspected hereditary NM disorders.

8:00 AM Anthony A. Amato, MD

Effective EDX Report WritingMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 19

(1) Discuss key components of quality EMG reports and (2) how to avoid language or terminology which is often misinterpreted.

8:00 AM Elizabeth A. Mauricio, MD Fasciculations, Myotonia and Myokymia

Multi-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 21

(1) Define fasciculations, myotonia, and myokymia, (2) explain the physiological basis for these spontaneous phenomena, (3) distinguish the discharges from one another, (4) list the anatomical sites at which these discharges are generated,(5) discuss the diseases and disorders with which these phenomena are associated and their clinical significance, and (6) describe available therapies.

8:00 AM Ludwig Gutmann, MD

EthicsMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMMagnolia

(1) Recognize ethical issues in case studies by reviewing realistic cases that illustrate common ethical problems, (2) discuss the utilization of Guidelines for Ethical Behavior Relating to Clinical Practice Issues in NM and EDX Medicine in particular situations, (3) identify features of a case that distinguish it from other apparently similar cases, (4) acknowledge when exceptions to guidelines are justified, (5) discuss an approach to solving ethical dilemmas in clinical medicine

8:00 AM Introduction David A. Simpson, DO, MS

8:05 AM Conflicts of InterestDavid A. Simpson, DO, MS

8:25 AM Questionable EDX ReferralJohn W. Norbury, MD8:45 AM Ethical Issues With Disruptive Neurophysiology Technologist Raghav Govindarajan, MD 9:05 Maintaining Professionalism: Condescending Physician in the EDX Laboratory Jerry Morris, CNCT, MS, R.NCS.T.; Mary E. Franklin, CNCT, R. EEG T.


Brachial Plexopathies & Shoulder Girdle NeuropathiesMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMElmwood

(1) Demonstrate how to utilize EDX to identify and manage both common and uncommon shoulder girdle neuropathies in athletes, (2) explain how to apply EDX to diagnose traumatic plexopathies and determine the role of non-operative and operative care, (3) evaluate for proper nerve donors and recipients, (4) an update on new surgical techniques and the cutting edge surgical nerve transfer and re-construction procedures for peripheral nerve and brachial plexus disorders, and (5) discuss the role of motor NCS, sensory NCS, and EMG in the pre and post-operative evaluation of nerve injuries. Attendees are encouraged to bring their own cases for discussion.

8:00 AM Joseph H. Feinberg, MD

Stem Cell Therapy and Other Novel Therapeutic Approaches in ALS: From Bench to BedsideAdvanced • 1.5 CME/CEU • 8:00 - 9:30 AMRosedown

(1) Review the expectation and unmet needs from stem cells and gene therapy in ALS, (2) discuss the preclinical data in ALS supporting novel therapeutic approaches and existing data on trials in people, (3) share the challenges and opportunities for these approaches, (4) explain recent progress in trials designs and pharmacological therapies, (5) discuss novel therapeutics in ALS including use of antisense oligonucleotides for familial ALS, gene silencing approaches for SOD1 and C9orf72 ALS and different stem cell therapies under development, and (6) discuss improving study design in ALS.

8:00 AM IntroductionNizar Souayah, MD

Special Interest Groups

Symposiums

E ElectrodiagnosticN NeuromuscularM MusculoskeletalThursday Academic/PracticeRelatedAP

N

E

NE

N

MNE

N

23

8:05 AM Stem and Gene Therapies in ALS: Expectations and Unmet Needs Nizar Souayah, MD 8:20 AM Stem Cell Therapy, RNA and Gene Therapy in ALSMerit E. Cudkowicz, MD, MSc 8:50 AM Discussion and Q & A 8:55 AM What Else is Happening in ALS: Optimizing Pharmacologic Therapies and Trials Designs Jeremy M. Shefner, MD, PhD


Help Your Movement Disorders Colleagues Sort Out Organic and Functional MDAdvanced • 1.5 CME/CEU • 8:00 - 9:30 AMOak Alley

(1) Review the description of “kinesiology”, (2) utilize an EMG machine to conduct kinesiology study, and (3) recognize the EMG patterns of the real and psychogenic tremor, myoclonus, and dystonia.

8:00 AM IntroductionJau-Shin Lou, MD, PhD, MBA 8:05 AM What is Kinesiology? Jau-Shin Lou, MD, PhD, MBA 8:35 AM Discussion and Q & A 8:40 AM Case Demonstrations Robert Chen, MBBChir, MSc, FRCPC 9:20 AM Discussion and Q & A

Biological Therapies in NM DiseasesAdvanced • 1.5 CME/CEU • 8:00 - 9:30 AMMelrose

(1) Describe the use of intravenous immunoglobulin in immune-mediated NM disease, (2) describe the use of monoclonal antibodies as treatment modalities in NM disease, and (3) discuss recent data stem cell therapy for MG.

8:00 AM IntroductionPerry K. Richardson, MD 8:05 AM Intravenous Immunoglobulin in Immune Mediated Neurological DiseaseTodd D. Levine, MD

8:30 AM Monoclonal Antibodies As Therapy in NM DiseaseTodd D. Levine, MD 8:55 AM Discussion and Q & A

9:00 AM Oligonucleotide Based Strategies in NM Disease Timothy M. Miller, MD, PhD


Member Practice Issues Open ForumMulti-Level • 8:00 am - 9:30 amNewberry

The Professional Practice Committee (PPC) will be hosting an open forum for members to discuss any current issues or trends they are seeing in their practices and that the PPC may be able to address either with advice or, potentially, through the creation of a new position statement.

Plenary 2- Insight and Innovations in NM MedicineBasic/Advanced • 2 CME/CEU • 10:00 AM - 12:00 PMGrand Ballroom A & B

10:00 AM WelcomeVern C. Juel, MD 10:05 AM President’s Research Initiative Awards, Recognition of Legacy Gift: Vanda Lennon Vern C. Juel, MD

10:20 AM IntroductionVern C. Juel, MD 10:25 AM Measurement of NM Diseases in the Clinic Setting Edward H. Lambert Lecture, Ted M. Burns, MD 11:00 AM Introduction Vern C. Juel, MD 11:05 AM Innovative Technology for Patients with NM Disorders: Towards Improving Upper Extremity Function Stuart Reiner Lecture, Jay J. Han, MD 11:45 AM ClosingVern C. Juel, MD 11:50 AM Connect with the Speakers - Informal Discussion with Speakers

Abstract Poster Session IMulti-Level • 1 CME/CEU • 11:30 AM - 12:30 PMHall of Research - Exhibition Center A & B, 2nd level

Poster viewing - Authors for posters 1 - 109 will be available to discuss their research.


Plenary

Open Forum

MNE

N

MNE

MNE

Poster Session

MNE AP

24

Basics With the ExpertsMulti-Level • 3 CME/CEU • 1:30 pm - 5:30 pmGrand Salon A

(1) Explain the basic concepts underlying NCSs and approach to the study, (2) teach how to correctly perform and interpret NCSs in the upper and lower extremities, (3) review specialized studies including RNS, cranial nerve studies, blink reflex, short and prolonged exercise studies in channelopathies, (4) review the basic concepts of needle EMG and (5) discuss common technical considerations and pitfalls when performing studies and how to troubleshoot them. 1:30 PM Introduction Mohammad Kain Salajegheh, MD 1:40 PM Basics of NC and Approach to Study Mohammad Kian Salajegheh, MD 2:10 PM Upper and Lower Extremity NCSs Kelly G. Gwathmey, MD

3:00 PM Break 4:00 PM Specialized Studies and Needle EMG Basics Aaron Izenberg, MD 4:50 PM Study Pitfalls and Troubleshooting Joseph M. Choi, MD 5:20 PM Discussion and Q & A

Electrodiagnosis and US for Evaluation of Focal Neuropathies of the Upper Limb Multi-Level • 3 CME/CEU • 1:30 - 5:30 PMGrand Ballroom A

(1) Review the capabilities of high frequency US to image the peripheral nervous system, (2) review the important components of the EDX evaluation for assessment of focal neuropathies, (3) review potential contributions of US and EDX for assessment of focal neuropathies including the relative strengths and weaknesses of each, and (4) discuss case examples of challenging focal neuropathies with improved management decisions provided by the information gained from the use of both US and EDX techniques.

1:30 PM IntroductionJeffrey A. Strakowski, MD 1:35 PM Introduction and Live Scanning of the Upper and Lower Limbs Jeffrey A. Strakowski, MD 2:15 PM Upper Limb Entrapment Syndromes

Jun Kimura, MD 3:00 PM Break 4:00 PM US for Focal NeuropathiesMichael S. Cartwright, MD 4:45 PM - Combining EDX and US for Assessment of Focal Neuropathies. Jeffrey A. Strakowski, MD 5:15 PM Discussion and Q & A

Genetics of Hereditary Neuropathy and MyopathyMulti-Level • 3 CME/CEU • 1:30 - 5:30 PMGrand Ballroom B

(1) Recognize clinical phenotypes and genotypic overlaps of common inherited neuropathies, distal myopathies, myotonic dystrophies and LGMD, (2) review available tests, and enhance targeted selection of genetic tests, (3) learn recent developments, and (4) devise a safe beneficial exercise program, and recognize the general risks and benefits of exercise for inherited NM disorders.

1:30 PM IntroductionBassam A. Bassam, MD

1:35 PM Genetics of Distal Myopathies Margherita Milone, MD, PhD

2:00 PM Genetics of Hereditary Neuropathy, Overview Bassam A. Bassam, MD 2:25 PM Myotonic Disorders and Genetics of Myotonic DystrophiesSaid R. Beydoun, MD 2:50 PM Discussion and Q & A 3:00 PM Break

4:00 PM Genetics of LGMDTeerin Liewluck, MD 4:30 PM Exercise for Progressive Myopathies, Risks and BenefitsAndrew J. Skalsky, MD


CrossfiresMulti-Level • 3 CME/CEU • 1:30 - 5:30 PMGrand Salon B

(1) If antibody testing and muscle biopsy is always indicated and helpful. The opposing views will help to identify the strengths and challenges of the diagnosis, (2) if quality measures in neuropathy and other NM disorders are useful tools for day-to-day use, (3) if genetic testing in limb girdle muscular dystrophy


Courses

NE

NE

NE

E

25

is useful, and (4) if the rating scales in NM disorders are useful primarily for research.1:30 PM IntroductionGhazala R. Hayat, MD 1:34 PM Quality Measure in Neuropathy and Other NM Disorders: ProsPeter D. Donofrio, MD 1:54 PM Quality Measures in Neuropathy and Other NM Disorders: Cons Neil A. Busis, MD 2:13 PM Discussion and Q & A 2:18 PM Genetic Testing in Limb Girdle Muscular Dystrophy: Pros Madhuri Hegde, PhD., FACMG 2:37 PM Genetic Testing in Limb Girdle Muscular Dystrophy: Cons Pushpa Narayanaswami, MBBS, DM, FAAN 2:55 PM Discussion and Q & A3:00 PM Break 4:00 PM Inclusion Body Myositis; Antibody and Muscle Biopsy Needed in Each Patient: Pros Alan Pestronk, MD 4:20 PM Inclusion Body Myositis; Antibody Testing and Muscle Biopsy Needed in Each Patient: Cons Anthony A. Amato, MD 4:40 PM Discussion and Q & A 4:45 PM Rating Scales in NM Disorders: Clinic Use: ProsWilliam W. Campbell, MD 5:05 PM Rating Scales in NM Disorders: Clinic Use: Cons Vinay Chaudhry, MD 5:25 PM Discussion and Q & A

Principles of NCS and Needle EMG: What We Measure and What It MeansBasic • 3 CME/CEU • 1:30 - 5:30 PMGrand Salon C

(1) Review the foundational knowledge required to understand NCS and needle EMG, (2) review the measurements made during the NCS and needle EMG and what they signify,(3) review how the different forms of demyelination and axon loss affects the NCS and needle EMG measurements, (4) present a variety of focal and generalized disorders to illustrate these teaching points, and (5) demonstrate through case studies how appropriate pairing of the sensory NCS is used to localize focal axon loss lesions, how the motor NCS identify the underlying pathology and its severity, and how the needle EMG confirms the NCS findings and further indicates the temporal pace of the

underlying process and prognostication. 1:30 PM IntroductionMark A. Ferrante, MD 1:35 PM NCS: What We Measure and What It Means Mark A. Ferrante, MD 2:50 PM Discussion and Q & A

3:00 PM Break

4:00 PM Review EDX CasesBryan E. Tsao, MD


EDX Laboratory Accreditation - Why and How

Multi-Level • CME/CEU • 3:30 - 4:00 PMGrand Ballroom A

EDX Laboratory Accreditation is a voluntary peer review process that identifies and acknowledges EDX laboratories for achieving and maintaining the highest level of quality, performance and integrity based on professional standards developed by AANEM. Come hear about the process and benefits of having your lab accredited.

10:00 AM Vincent J. Tranchitella, MD and Peter Q. Warinner, MD


Information Session

E

AP

Abstract Award Winners’ ReceptionMulti-Level • 1.5 CME/CEU • 5:30 pm - 7:00 pm

Hall of Research - Exhibition Center C, 2nd levelFor more information see page 45

NE

Order the

2016 Online Coding Guideat aanem.org

26

Idiopathic Brachial PlexopathyMulti-Level • 8:00 - 9:30 AMGrand Salon 3

(1) Identify the pertinent anatomy and clinical criteria for the classic phenotype of Neuralgic Amyotrophy (Parsonage-Turner Syndrome) based on history and physical examination, (2) review the differential diagnosis for idiopathic brachial plexopathy and how EDX studies and US can be helpful in distinguishing between these possibilities, and (3) describe the natural history and treatment of neuralgic amyotrophy.

8:00 AM John W. Norbury, MD

Pelvic Floor Dysfunction Multi-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 6

(1) Explain why the history and physical are critical in understanding pelvic floor dysfunction, (2) recognize some common MSK masqueraders of pelvic pain and pelvic floor dysfunction, (3) discuss the limitations of EDX in the evaluation of pelvic floor dysfunction, and (4) understand that the history and physical exam are key to establishing a diagnosis in patients with pelvic floor dysfunction.

8:00 AM Andrew H. Dubin, MD, MS

Immune Mediated NM DisordersMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 9

(1) Discuss current therapies of autoimmune neuropathies, and (2) explain treatment and diagnostic issues.

8:00 AM Clifton L. Gooch, MD

Post Traumatic/Surgical EDX Evaluation Multi-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 10

(1) Discuss common and uncommon post traumatic and post surgical NM disorders, (2) discuss the role of electrophysiologic studies for evaluating post traumatic and post surgical NM disorders, and (3) discuss treatment and outcomes of post traumatic and post surgical NM disorders.

8:00 AM Mark A. Ross, MD

SpasticityMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 13

(1) Review basic and more advanced spasticity assessment and management strategies, (2) differentiate advantages and disadvantages of spasticity and indications for treatment, and (3) discuss non-pharmacologic and pharmacologic management including appropriate use of infusion pumps and injection therapies

8:00 AM Kathryn A. Stolp, MD, MS

EDX of the FootMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 15

(1) Which tests (NCS & EMG) constitute the optimal EDX evaluation of the foot, (2) assess the role of needle EMG in EDX of the foot, (3) assess the differential diagnosis for neuropathic foot pain, including entrapment neuropathies in the foot/ankle, (4) compare the electrophysiologic findings and clinical presentation in tarsal tunnel syndrome vs peripheral neuropathy, and (5) evaluate when further work-up is clinically warranted.

8:00 AM David R. Del Toro, MD

Chemodenervation Multi-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 16

(1) Explain the practical aspects of chemodenervation with the botulinum toxins in focal dystonia and spasticity, (2) discuss the role of EMG guidance in the recognition of dystonic EMG patterns and choice of candidate muscles for injection, and(3) discuss dosing differences/relationships among available toxins.

8:00 AM Janice M. Massey, MD

Neuropathic PainMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 18

(1) Provide an evidence-based approach to selecting medications to treat neuropathic pain, (2) explain the advantages and disadvantages of each of the common approaches to managing neuropathic pain, (3) discuss the nonpharmacologic strategies for dealing with neuropathic pain, and (4) outline the principles used to decide whether a topical preparation might be a good therapeutic choice for neuropathic pain.8:00 AM Benn E. Smith, MD

Sept. 16thFriday

MNE

NE

NE

NE

NE

NE

NE

Registration: 8:00 AM - 4:00 PMPosters: 8:00 AM - 2:00 PMExhibit Hall: 9:00 AM - 4:00 PMSpeaker Ready Room: 7:00 AM - 4:00 PM

Ask The Expert Sessions*

MN

*No breakfast provided at Ask the Experts Sessions.Seating is limited - come early to claim a seat.

27

Botulinum Toxin for PainMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 19

(1) Cite painful conditions that have been treated with botulinum toxin, (2) review literature support and limitations for treatment of painful conditions using botulinum toxin,(3) summarize techniques that other participants in the roundtable are using for treatment of pain, (4) explain experiences using botulinum toxin for the treatment of pain, and (5) utilize botulinum toxin to manage patients with pain.

8:00 AM Atul T. Patel, MD

NM USMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 21

(1) Explain how NM US is incorporated into an EDX laboratory, (2) discuss NM conditions in which US can improve the diagnosis and treatment, and (3) review the general aspects of billing for NM US.

8:00 AM Francis O. Walker, MD

What Reference Values and Nerve Conduction Techniques Should I Use in My Practice? Multi-Level • 1.5 CME/CEU • 8:00 - 9:30 AMGrand Salon 4

(1) Understand how high quality normative data (reference values) are derived, (2) learn about the normative data taskforce and the results of that effort that identified techniques and reference values for common NCSs that are useful resources for electrodiagnosticians, and (3) learn how easy it is to incorporate these NCS techniques into your practice.

8:00 AM Timothy R. Dillingham, MD, MS

Autonomic Disorders in Your PracticeAdvanced • 1.5 CME/CEU • 8:00 - 9:30 AMElmwood

(1) Identify the role of non-invasive autonomic testing, the technique of one or more tests of Sweating (QSART, TST, SSR) and the technique of one or more tests of Cardiovascular function (HRDB, Valsalva maneuver and Tilt table testing), (2) explain the principles of contact heat evoked potential stimulation, one or more human disease states in which CHEPS may prove useful in documenting spinothalamic pathway

dysfunction, and the technique and value of skin biopsy in small fiber neuropathy, and (3) review the diagnostic criteria for orthostatic intolerance, an approach to the evaluation of neurogenic orthostatic hypotension and the treatment principles in the management of orthostatic intolerance and neurogenic orthostatic hypotension.

8:00 AM Introduction Jasvinder P. Chawla, MBBS, MD, MBA 8:05 AM Basic and Noninvasive Studies in Diagnosing Autonomic Dysfunction Jasvinder P. Chawla, MBBS, MD, MBA 8:30 AM Advanced and Invasive Autonomic Testing for Diagnosing Small Fiber NeuropathyBenn E. Smith, MD 8:55 AM Management of Neurogenic Orthostatic HypotensionBrent P. Goodman, MD 9:20 AM Discussion and Q & A EMG Reports: Issues of Report Formulation and Conveying InterpretationMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMOak Alley

Improve patient care by providing a concise interpretation of EMG data and assessment of their clinical significance for the referring physician.

8:00 AM IntroductionWinfried A. Raabe, MD 8:05 AM Do Referring Physician’s Understand our EMG Reports?Elizabeth A. Mauricio, MD 8:25 AM Formulation of the EMG Report Kerry H. Levin, MD 8:45 AM Is a Clinical Interpretation (Beyond the EDX Interpretation) Helpful or Harmful to the Referring Physician?Devon I. Rubin, MD


From Primary Demyelination to NodopathyAdvanced • 1.5 CME/CEU • 8:00 - 9:30 AMJasperwood

Recognize the concept of pathology at the node of Ranvier and how it affects nerve conduction testing for primary demyelinating neuropathies.

8:00 AM IntroductionMark B. Bromberg, MD, PhD

E ElectrodiagnosticN NeuromuscularM MusculoskeletalFriday Academic/PracticeRelatedAP


M

N

N

MN

N

E

E

Symposiums - Morning

N

28

8:05 AM Nodopathies and Guillain–Barré Syndrome Mark B. Bromberg, MD, PhD 8:40 AM Nodopathies and CIDP Hans D. Katzberg, MD

9:20 AM Discussion and Q & A Emerging Tools in the Diagnosis of Muscle DiseaseAdvanced • 1.5 CME/CEU • 8:00 - 9:30 AMRosedown

(1) Describe a logical approach to the diagnosis of congenital muscular dystrophy based on clinical and laboratory features, (2) discuss the utility of genomic sequencing in the diagnosis of muscle disease, (3) discuss the role of US in diagnosing myopathies. 8:00 AM Introduction Perry K. Richardson, MD

8:05 AM Diagnostic Approach to the Congenital Muscular Dystrophies Carsten G. Bönnemann, MD 8:25 AM Integrating Old and New Tools in the Diagnosis of Genetic Muscle Disease Carsten G. Bönnemann, MD 8:50 AM Discussion and Q & A 9:00 AM US in the Diagnosis of Myopathies Jahannaz Dastgir, DO 9:25 AM Discussion and Q & A

Plenary 3 - Insight and Innovation in NM MedicineBasic/Advanced • 1.5 CME/CEU • 10:00 AM - 12:00 PMGrand Ballroom A & B

10:00 AM WelcomeVern C. Juel, MD 10:05 AM Awards: Lifetime Achievement, Distinguished Physician, Distinguished Researcher, Honorary Membership, Advocacy, and Service Award: Lawrence H. Phillips, II, MDVern C. Juel, MD 10:20 AM Introduction Vern C. Juel, MD

10:25 AM Developing Multidisciplinary Clinics for NM Care and ResearchRichard K. Olney Lecture, Merit E. Cudkowicz, MD, MSc 11:00 AM IntroductionVern C. Juel, MD 11:05 AM Emerging Gene Therapies for NM Disease: SMA as PrototypeJohn T. Kissel, MD 11:40 AM ClosingVern C. Juel, MD 11:45 AM Connect with the Speakers: Informal Discussion with Speakers

Abstract Poster Session IIMulti-Level • 1 CME/CEU • 11:30 AM - 12:30 PMHall of Research - Exhibition Center A & B

Poster viewing - Authors for posters 110 - 207 will be available to discuss their research.

CME certification was excluded for abstracts 208-17 and cannot be claimed as part of participation for the posters sessions of the 2016 Annual Meeting.

Plenary


Poster Session

MNE

MNE AP

MNE

29

Industry Forum - Alnylam Pharmaceuticals

Emerging Therapies for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN): The potential role of RNAi therapeutics

Multi-Level • 12:00 - 1:00 PMHilton New Orleans Riverside - Exhibition Center C, 2nd level

Objectives: (1) Describe the unmet medical needs in hATTR-PN, (2) review the natural history and clinical assessment tools in hATTR-PN, and (3) discuss the development of investigational RNAi therapeutics as a potential treatment option for patients with hATTR-PN. Hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN), also known as familial amyloidotic polyneuropathy (FAP), is an inherited, progressive disease leading to death within 5-15 years. It results from a mutation in the transthyretin (TTR) gene, causing misfolded TTR proteins to accumulate as amyloid fibrils predominantly in peripheral nerves and other organs. hATTR-PN affects ~10,000 patients worldwide, and can cause a range of neuropathy symptoms resulting in significant disability and death. Due to the wide range of symptoms, patients may remain undiagnosed. Current treatment options for hATTR-PN patients are limited/ aren’t available or suitable for all patients; thus there is a significant need for novel therapeutics for these patients. This forum aims to provide an overview of the clinical presentation, challenges in diagnosis, natural history, current treatment options and the unmet medical need of hATTR-PN. Additionally, it will review emerging therapies and the potential role of RNA interference as a treatment option.Presenters:Dr. Thomas Brannagan (USA) , Dr. Dianna Quan (USA), Dr. Alejandra Gonzales-Duarte (Mexico) This activity is sponsored by Alnylam Pharmaceuticals. This activity is not part of the official scientific program of the AANEM. Food will be provided by the AANEM for session attendees. Seating is limited.

Neuropathy Associated with Systemic Disease

Multi-Level • 3 CME/CEU • 1:30 AM - 5:30 PMGrand Ballroom A

(1) Describe the appropriate work-up for neuropathy and malignancy associated with paraproteinemia, (2) determine the diagnosis and management of patients with neuropathy associated with amyloidosis, (3) differentiate among systemic conditions that cause multiple mononeuropathies, (4) review peripheral nerve manifestations of human immunodeficiency virus, and (5) discuss the pathologic effects of chemotherapeutic and other pharmaceutic agents on the peripheral nervous system, and devise a management program for patients with chemotherapy-induced neuropathy.

1:30 PM IntroductionZachary N. London, MD 1:35 PM Neuropathy Associated With Paraproteinemia Zachary N. London, MD 2:00 PM Neuropathy in Amyloidosis Sarah E. Berini, MD 2:25 PM Multiple Mononeuropathies Ryan D. Jacobson, MD


3:00 PM Break 4:00 PM Neuropathy Associated With Chemotherapeutic Agents Raymond S. Price, MD 4:25 PM HIV-related Neuropathies David M. Simpson, MD 4:50 PM Clinical Evaluation and Treatment of Neuropathy in Cancer Michael D. Stubblefield, MD 5:15 PM Discussion and Q & A

Immunotherapy in NM Disease: Current Concepts and Future DirectionsMulti-Level • 3 CME/CEU • 1:30 - 5:30 PMGrand Ballroom B

(1) Recognize the basic mechanism of action and rationale for using available immunotherapies in autoimmune NM disease, (2) describe the approach to managing NM patients with immunotherapies, (3) review the appropriate therapeutic options for specific NM diseases, and (4) discuss immunotherapeutics on the horizon for the treatment of autoimmune NM diseases.1:30 PM Introduction Jeffrey T. Guptill, MD 1:35 PM Practical Care Aspects for the Use of Immune Modulating Drugs in the Treatment of NM DisordersJames F. Howard, MD2:15 PM Treatment of Immune-mediated Neuropathies Jeffrey A. Allen, MD

2:55 PM Discussion and Q & A 3:05 PM Break 4:05 PM Treatment of Immune-mediated NMJ Diseases and Myopathies Jeffrey T. Guptill, MD 4:45 PM Novel Therapeutic approaches for AutoimmunityMatthew N. Meriggioli, MD 5:25 PM Discussion and Q & A


Courses

N

N

30

MSK Medicine: Toe to HipMulti-Level • 3 CME/CEU • 1:30 - 5:30 PMGrand Salon B

(1) Enhance details of MSK disorders that are part of the differential diagnosis for leg pain, weakness and numbness, (2) delineate physical examination procedures to clarify the differential diagnosis of MSK disorders of the lower extremity, and (3) provide algorithms for diagnostic testing for suspected MSK causes of leg pain, weakness, and numbness. 1:30 PM IntroductionAnthony E. Chiodo, MD

1:40 PM The Hip Phillip T. Henning, DO 2:20 PM The Knee Anthony E. Chiodo, MD

3:00 PM Break 4:00 PM Doctor My Leg Hurts and Sometimes Does Weird ThingsAndrew H. Dubin, MD, MS 4:40 PM The Foot and Ankle Ann T. Laidlaw, MD 5:20 PM Discussion and Q & A Common PolyneuropathiesMulti-Level • 3 CME/CEU • 1:30 - 5:30 PMGrand Salon C

(1) Recognize and evaluate different forms of diabetic peripheral neuropathies including diabetic sensorimotor peripheral neuropathy, neuropathy associated with glucose impairment, treatment induced diabetic neuropathy and diabetic lumbosacral radiculoplexus neuropathy, (2) identify inherited neuropathy and apply an algorithmic approach to genetic testing, (3) assess for association of monoclonal gammopathies with peripheral neuropathy and determine need for further testing and review available treatment options for distal acquired demyelinating symmetric neuropathy, and (4) recognize the different neuropathy phenotypes associated with vitamin deficiencies, medication and toxins and review the prognosis of these conditions.1:30 PM IntroductionMichelle L. Mauermann, MD 1:35 PM Diabetic Peripheral Neuropathies Christopher H. Gibbons, MD, MMSc

2:20 PM Inherited Peripheral Neuropathies Mario Saporta, MD, PhD

3:00 PM Break 4:00 PM Paraproteinemic Neuropathies Michelle L. Mauermann, MD 4:40 PM Peripheral Neuropathies due to Vitamin Deficiency, Toxins and Medications Nathan P. Staff, MD, PhD 5:20 PM Discussion and Q & A

Cutting Edge USAdvanced • 1.5 CME/CEU • 1:30 - 3:00 PMGrand Salon A

(1) Discuss imaging of small nerves in the arm and leg,(2) Explain the benefits of ultra-high resolution transducers, and (3) learn how to incorporate US into a busy and efficient EDX laboratory.

1:30 PM IntroductionMichael S. Cartwright, MD 1:35 PM High-Resolution Nerve Imaging Lisa D. Hobson-Webb, MD 2:00 PM US of Small Nerves and Fascicular Branches Peter Inkpen, MD 2:25 PM US in Combination with EMG David C. Preston, MD 2:50 PM Discussion and Q & A

EDX Laboratory Accreditation - Why and HowMulti-Level • 3:30 - 4:00 PMGrand Ballroom A

EDX Laboratory Accreditation is a voluntary peer review process that identifies and acknowledges EDX laboratories for achieving and maintaining the highest level of quality, performance and integrity based on professional standards developed by AANEM. Come hear about the process and benefits of having your lab accredited.

3:30 PM Vincent J. Tranchitella, MD and Peter Q. Warinner, MD


Symposium - Afternoon

Information Sessions

MN

MN

MN

AP

31

Quality Issues and Fraud and AbuseMulti-Level • 3:30 - 4:00 PMGrand Salon A

This informal session will (1) Identify the most common types of fraud and abuse in EDX medicine, both NCS and EMG, (2) explain how fraud and abuse practitioners attempt to hide bad practices, (3) discuss how to recognize and combat fraud and abuse in participants’ communities and practices, (4) review the negative effect it has on those practicing good quality EDX medicine, and (5) attempt to define the difference between medically necessary testing, abuse and fraud through EMG/NCV examples

4:00 PM IntroductionJohn E. Robinton, MD

4:05 PM Neurology Testing Quality and Billing Fraud, Waste and Abuse Watchouts Adam Seidner, MD, MPH 4:30 PM Red Flags and Keys to Neurodiagnostic Fraud InvestigationsMitchell Sherrod, MPA, BSCJ, AHCFI 4:55 PM Fraud or Abuse? John E. Robinton, MD 5:15 PM Discussion and Q & A


AANEM Annual Business Meeting5:30 - 6:30 PMGrand Salon D

At this meeting the chairs of several committees will report on recent activities of importance to the membership. Nominations for the Board will be presented.

AANEM fellow and active members are especially encouraged to attend and vote.

AANEM

ANNUAL MEETING

Show your EDX expertise by becoming

an ABEM diplomate

Registration:Oct. 1 - Nov. 30, 2016Exam dates:March 1 - 4, 2017

ABEM 2017Are you interested in showing your

expertise by taking the only certifying exam focusing on EDX medicine?

Registration for the ABEM initial exam opens October 1.

For more information, please visitwww.abemexam.org

AANEM CENTERC A R E E R

The AANEM Career Center

has the most coveted selection of neurologist, physiatrist, and

electroneurodiagnostic technologist jobs. AANEM Career Center is the official AANEM job board and is

the first place employers go to list their opportunities.

Visit www.aanem.org/jobs to browse current opportunities or to

post a position.

AP

Open to all attendees

32

Diabetic NeuropathyMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMOak Alley

(1) Discuss the possible roles of population screening in diabetic neuropathy, (2) recognize the relevancy of myelinated nerves in diabetic neuropathy, and (3) describe the spectrum of small fiber neuropathy and the roles of skin biopsy.

8:00 AM Introduction Jau-Shin Lou, MD, PhD, MBA

8:05 AM How Can I Diagnose Peripheral Neuropathy and Not Spend a Fortune Amanda C. Peltier, MD, MS 8:40 AM Discussion and Q & A 8:45 AM Exercise in Diabetic Neuropathy and the ADAPT-Activity for People With Diabetic Polyneuropathy Mamatha Pasnoor, MD 9:20 AM Discussion and Q & A

Developing Education in NM and EDXMulti-Level • 1.5 CME/CEU • 8:00 - 9:00 AMElmwood

(1) Share knowledge and expertise for assessment methods of NM and EDX trainees, (2) share knowledge and expertise for integrating quality improvement into NM and EDX training programs, and (3) network with clinician educators to develop and carry out educational research.

8:00 AM Introduction Dianna Quan, MD

8:05 AM Workplace-based Assessment of EDX Skills Among NM and EDX TraineesAndrea N. Leep Hunderfund, MD, MHPE 8:30 AM Integrating QI into NM and EDX Training ProgramsPushpa Narayanaswami, MBBS, DM, FAAN 8:55 AM How You Can Advance NM EducationTaylor B. Harrison, MD 9:20 AM Discussion and Q & A

InstrumentationMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMJasperwood

Discuss (1) basic electronic circuits including Ohms’ law and properties of alternating current, (2) electrodes and electrode types, (3) amplifiers, (4) filters, (5) analog to digital conversion, (6) averaging and signal to noise ratio, (7) displays, (8) stimulators and stimulator properties, (9) interference, and (10) electrical safety.

8:00 AM Introduction James Lewis, CNCT, R.NCS.T 8:05 AM Instrumentation Sanjeev D. Nandedkar, PhD 9:20 AM Discussion and Q & A

Advocacy Challenges in EDX MedicineMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AMRosedown

(1) Identify regulatory and reimbursement issues facing AANEM members, (2) discuss challenges and obstacles ahead due to the repeal of SGR and a greater emphasis on quality and alternative payment models, (3) describe AANEM’s lobbying and advocacy efforts, (4) discuss how the rapid regulatory changes are affecting our field, and (5) contribute to ongoing advocacy efforts.

8:00 AM IntroductionRaghav Govindarajan, MD 8:05 AM Advocacy Challenges Facing AANEMVincent J. Tranchitella, MD 8:25 AM Quality in EDX Medicine-Is It A Myth? Peter A. Grant, MD 8:45 AM Advocacy Efforts by AANEM and How You Can Get InvolvedMillie Suk, JD, MPP 9:05 AM MACRA-Sail or Sink? Raghav Govindarajan, MD 9:25 AM Discussion and Q & A


Sept. 16thSaturday Registration: 8:00 - 10:00 AMSpeaker Ready Room: 7:00 - 11:30 AM

AP

MN

E

AP

33

W03AS Noninvasive Ventilation in NM DisordersMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 am

(1) Discuss and demonstrate evaluation of sleep apnea and related disorders in a NM clinic, (2) gain hands-on experience with the range of treatments available for NM sleep disorders, including CPAP, BiPAP, noninvasive ventilators, and diaphragmatic pacers, and (3) gain understanding of: physiology; indications for use; equipment and interfaces; programming and data collection; and insurance and coding issues for these disorders.

8:00 AM Clark W. Pinyan, MD, MPH W05AS Cranial NCS and EMG TestingAdvanced • 1.5 CME/CEU • 8:00 - 9:30 AM

Discuss neurophysiological testing of the cranial nerves, including the performance of (1) blink reflexes with both electrical and mechanical stimuli, (2) seventh NCSs, and(3) eleventh nerve testing. EMG of key muscles that complement the cranial NCS also will be discussed.

8:00 AM Kathleen D. Kennelly, MD, PhD W07AS Measuring Jitter With Concentric ElectrodesAdvanced • 1.5 CME/CEU • 8:00 - 9:30 AM

(1) Demonstrate how jitter can be measured using concentric electrodes and (2) identify machine settings and limitations. Must be familiar with the basic concepts of SFEMG.

8:00 AM Donald B. Sanders, MD W10AS EMG Needle BasicsBasic• 1.5 CME/CEU • 8:00 - 9:30 AM

(1) Utilize electrophysiologic techniques related to the needle EMG, (2) apply a problem-directed approach to the study,(3) identify insertional and spontaneous activity, and(4) recognize the characterization of MUAP morphology and recruitment in normal and diseased states.

8:00 AM Atul T. Patel, MD

W17AS EMG Evaluation of TremorAdvanced • 1.5 CME/CEU • 8:00 - 9:30 AM

(1) Discuss single and multiple channel recording techniques for tremor, (2) compare and contrast the usefulness of needle versus surface EMG in conducting tremor analyses, and (3) recognize common tremor patterns seen in Parkinson’s disease, essential tremor, dystonia, and orthostatic tremor.

8:00 AM Mark Hallett, MD

W21AS NCS PitfallsBasic • 1.5 CME/CEU • 8:00 - 9:30 AM

(1) Identify common instrumentation, physiologic, and operator errors, (2) alter recording electrode montages and use the instrument’s filters to help optimize the recording of motor and sensory potentials, and (3) minimize stimulus artifact interference with waveform recording.

8:00 AM Bassam A. Bassam, MD

W23AS NCS UncommonAdvanced • 1.5 CME/CEU • 8:00 - 9:30 AM

(1) Place stimulating and recording electrodes for optimal recordings of uncommon nerves, (2) adjust the stimulation intensity and duration, and (3) adjust machine settings for appropriate recordings.

8:00 AM Eric J. Sorenson, MD

W27AS Repetitive Nerve StimulationBasic • 1.5 CME/CEU • 8:00 - 9:30 AM

See description on page 18, (W27C)8:00 AM Vettaikorumakankav Vedanarayanan, MD, FRCPC W31AS SFEMG Basic/AdvancedMulti-Level • 1.5 CME/CEU • 8:00 - 9:30 AM

Acquire skills in SFEMG recordings using volitional and axonal microstimulation techniques. Registrants are expected to be familiar with the basic concepts of SFEMG techniques.

8:00 AM James M. Gilchrist, MD

EN NeuromuscularM MusculoskeletalSaturdayWorkshops




N

E

NE

E

NE

E

E

E

E

Electrodiagnostic Academic/PracticeRelatedAP

34

W32AS Ulnar TechniquesBasic • 1.5 CME/CEU • 8:00 - 9:30 AM

Perform (1) antidromic ulnar digital sensory responses, (2) motor NCS to hypothenar, deep ulnar-innervated musculature, (3) stimulation/recording techniques for dorsal ulnar cutaneous, first dorsal interosseous, and medial antebrachial cutaneous, and (4) mid-palm and inching techniques.

8:00 AM William W. Campbell, MD W41AS Gait Disorders in NM DiseaseBasic • 1.5 CME/CEU • 8:00 - 9:30 AM

Acquire skills to (1) discuss the common pathologic gait patterns seen in NM disease, (2) discuss how EDX findings can explain why pathologic gait patterns occur, (3) identify strategies that help compensate for the underlying biomechanical deficit so as to decrease fall risk.

8:00 AM James K. Richardson, MD

W45AS Cervical Radiculopathy/Brachial PlexopathyBasic • 1.5 CME/CEU • 8:00 - 9:30 AM

1) Review the anatomy of the brachial plexus, (2) describe the course through the brachial plexus that the sensory axons take for each sensory NCS, (3) discuss how the sensory NCS are paired so that lesion localization can be determined (i.e., to a specific brachial plexus element), (4), review how the motor NCS and the needle EMG study are used to further characterize the lesion (e.g., pathology, severity, rate of progression, prognosis), and (5) apply this approach to actual radiculopathy and plexopathy cases.

8:00 AM Mark A. Ferrante, MD

W46AS Paraspinal Mapping and the Evaluation of Lumbosacral Plexopathy/RadiculopathyBasic• 1.5 CME/CEU • 8:00 - 9:00 AM

See Description on page 18, (W46C)8:00 AM Andrew J. Haig, MD

W50AS Advanced Autonomic TestingAdvanced • 1.5 CME/CEU • 8:00 - 9:00 AM

Discuss the three quantitative tests of autonomic function using specialized equipment designed for autonomic reflex function testing: (1) sudomotor testing, (2) cardiovagal testing with heart-rate response to deep breathing, and (3) Valsalva maneuver testing to evaluate cardiovagal and adrenergic function.

8:00 AM Amanda C. Peltier, MD, MS W53AS Most Reliable Techniques for CTS EDXAdvanced • 1.5 CME/CEU • 8:00 am - 9:30 am

(1) Perform the NCS techniques required for the CTS Sensory Index, (2) design an EDX study for a patient with possible CTS, and (3) recite the most common pitfalls in EDX testing for CTS.

8:00 AM William S. Pease, MD

Plenary 4- - Insight and Innovation in NM MedicineBasic/Advanced • 1.5 CME/CEU • 10:00 am - 12:00 pmGrand Ballroom A & B

10:00 AM Welcome Vern C. Juel, MD 10:05 AM Awards: IFCN & Foundation Certificates Vern C. Juel, MD 10:20 AM IntroductionVern C. Juel, MD 10:25 AM The Economics of Specialty Pharmaceuticals Kevin A. Schulman, MD 11:05 AM Introduction Vern C. Juel, MD 11:10 AM 2017 Meeting VisionWilliam S. Pease, MD 11:20 AM ClosingVern C. Juel, MD

Plenary

E ElectrodiagnosticN NeuromuscularM MusculoskeletalSaturday Academic/PracticeRelatedAP

E

NE

ME

ME

E

E

MNE

35

AANEM FoundationSilent AuctionParticipate in the AANEM Foundation Silent Auction located outside the exhibit hall entrance area near Grand Ballrooms C-D.

All proceeds from the auction support the Foundation’s research and educational initiatives. Bid amounts placed over and above the “fair market value” are tax deductible to the extent of the law.

Want to support the Foundation but don’t want to bid? Donations to the Foundation may be made at the registration desk.

Auction Bidding Hours Wednesday & Thursday: 8:00 AM – 5:30 PM

Winning Bid Item Pickup HoursFriday: 10:00 AM – 4:00 PM

How to Bid: Place your bids using the number located in the right-hand corner of your name badge above the bar code. Once you’ve placed your bid check back often to make sure someone else has not outbid you! The winning bid numbers will be posted in the auction area on Friday, September 16, beginning at 10:00 am and all items must be claimed and paid by 5:30 pm. Payment may be made by cash, check, or credit card (MasterCard, Visa, and American Express). Payment is required prior to item pickup. Shipping is an additional charge.

2016 Social EventBroussard’s French QuarterFusion Dining Experience:

Saturday, September 17, 5:15 -7:30 PMCost: $125 per person*

Dishes fashioned with an exotic blend of French and Creole influences have made New Orleans a preferred destination for lovers of inspired cuisine the world over. Located right in the heart

of New Orleans’ Vieux Carre, or French Quarter, Broussard’s merges a mix of classic food, old architecture, and tradition for an experience to remember.

(Photo credit Foodographer.net)

Sponsored by:

Silent Auction Begins Wednesday

*Price includes hors d’oeuvres and drinks in the private courtyard before enjoying dinner. Restaurant will be closed for this special event. Transportation not included to allow attendees to enjoy the French Quarter before and after dinner.

Stop at the registration desk to purchase your ticket

36

Exhibit Hall HoursHilton New Orleans Riverside – Grand Ballroom C & D

Wed 5:30 PM - 7:00 PM Thurs 9:00 AM - 4:00 PM Fri 9:00 AM - 4:00 PM

Exhibitor List5 LGMD Consortium6 The ALS Association7 American Board of Psychiatry and

Neurology101 Cadwell Laboratories, Inc.102 Grifols USA, LLC104 Jari Electrode Supply106 US WorldMeds107 Corinthian Reference Laboratory108 Gene DX109 GE Healthcare110 KabaFusion, LLC111 University of Missouri112 MediMax Tech113 MT Pharma America114 International Biophysics Corporation117 Diplomat201 Allergan, Inc207 Alexion Pharmaceuticals

208 AxelaCare Healthcare Solutions, LLC210 MEPs, LLC / Digitimer Ltd212 Catalyst Pharmaceuticals213 Rochester Electro-Medical, Inc.215 Emory Genetics Laboratory216 Ipsen Biopharmaceuticals217 BioCure RX301 Natus Neurology 307 Shire308 Nihon Kohden America312 Mayo Medical Laboratories313 Coram CVS/specialty infusion services314 Merz Pharmaceuticals, LLC315 University of Utah - Cutaneous Nerve Lab316 Demos Medical Publishing317 Biofusion401 Sanofi Genzyme409 Option Care

411 The Electrode Store412 Ambu Inc.413 RDL Reference Laboratory414 Therapath Neuropathology415 Global Medical Imaging416 Ultragenyx Pharmaceutical Inc.417 MVAP Medical Supplies503 FUJIFILM VisualSonics, Inc505 Nova Labs506 WR Medical Electronics Company507 Biogen Idec508 KEGO FMI (Faith Medical Inc)512 Sarepta Therapeutics513 Hawaiian Moon514 Promptcare515 Elsevier

2016 AANEM Exhibit Floor Plan with Booth Assignments Grand Ballroom Suite C-D Hilton New Orleans Riverside

6 5

Cyber ALS LGMD

Café

ABPN

7 8

Visualsonics Grifols

503

Nova Labs

505 401 301 201 101 102

Biogen Jari

507 104

WR Med Option Nihon Axela CRL US World

506 Care Kohden Alexion Care 107 106

KEGO GE GeneDx

508 409 307 308 207 208 109 108

Elect St MEPs U of MO Kabafusion

Sarepta 411 210 111 110

HI Moon RDL Ref Lab AMBU Coram MML RST Elec Catalyst MT Pharma MediMax

513 512 413 412 313 312 213 212 113 112

Elsevier PromptCare GMI Therapath Univ UT Merz Emory Lab Int'l Biophys

515 514 415 414 315 314 215 Ipsen Diplomat 114

MVAP Ultragx Biofusion DEMOS Biocure

417 416 317 316 217 216 117

Genzyme

Shire

NOTE: All exhibits are based on an 8' x 10' footprint. This map is for identification of locations and is not drawn to scale. Layout is subject to change. Yellow areas are available as of date/time below.

Chemin Royale

CadwellAllerganNatus

Coffee Break Area

Entr

ance

Gra

phic

s

Entrance Entrance

Suites A-BPlenary SessionsBe

vera

ge S

tatio

nBr

ede

Silent Auction

Silent Auction

AANEM Booth

AANEMProduct Sales

Last Updated: 8/11/2016; 4:16 PM

514

Sarepta

Release of personal Information:By allowing an exhibitor to scan yourname badge you consent to release the following information to the exhibitor: first and last name, and email address. If you do not consent to release this informa-tion you may refuse to have your badge scanned by exhibitors

37

Alexion Pharmaceuticals New Haven, CT www.alexion.com Booth 207 Alexion is a global biopharmaceutical company focused on life-transforming therapies for patients with devastating, rare diseases. Alexion developed the first and only approved complement inhibitor for PNH & aHUS. The company is strengthening and broadening its complement portfolio, including evaluating complement inhibition in additional ultra-rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for two ultra-rare, life-threatening disorders.

Allergan, Inc Irvine, CA www.allergan.comBooth 201 Allergan (NYSE: AGN) is a unique, global pharmaceutical company focused on developing, manufacturing, and commercializing high quality generic and innovative branded pharmaceutical products for patients around the world. The Company has approximately 30,000 employees worldwide and maintains global headquarters in Dublin, Ireland. For more information, visit www.Allergan.com.

Ambu Inc. Glen Burnie, MD www.ambu.comBooth 412

Ambu manufactures and sells quality electrodes that optimize workflow, reduce costs, and improve patient care. Our full line of neurodiagnostic electrodes includes reusable and disposable products to help meet your everyday needs. Ambu offers innovative products such as our Neuroline 100% disposable cups. Made of a highly conductive Ag/AgCL, our cups offer low impedance levels for clear and precise readings while reducing the growing risk of cross contamination. We also specialize in a full line of needles and electrodes for IOM, EMG, NCS, EP, Sleep and EEG studies. Ambu designs our products with both the patient and physician in mind.

American Board of Psychiatry and Neurology Buffalo Grove, IL www.abpn.com Booth 7

The American Board of Psychiatry and Neurology serves the public interest and the professions of psychiatry and neurology by promoting excellence in practice through its

certification and maintenance of certification processes.

AxelaCare Healthcare Solutions, LLC Lenexa, KS www.axelacare.comBooth 208

AxelaCare is a national home infusion provider taking care of acute and chronic patients across the country. With more than 30 pharmacy locations and our extensive team of employed clinicians, our goal is to provide exceptional patient care. Services include anti-infectives, inotropes, parenteral nutrition, immunoglobulin, and other specialty infusions.

BioCure RX Houston, TX www.biocurerx.com Booth 217

BIOCURE Specialty Pharmacy is a privately held company that specializes in high cost, high patient out-of-pocket, and clinically complex therapies that involve nursing care and/or training. BIOCURE is designed to provide solutions for the medical professionals, commercial payers, manufacturers, and most importantly the patient through the most advanced technologies

Biofusion Torrance, CA www.biofusioninc.com Booth 317

Biofusion is a leading national provider of IgG therapy for autoimmune and neuromuscular diseases. We service patients with Medicare as well as most major commercial payer sources and we take responsibility for treatment authorizations. Our specialized clinicians, pharmacists and nurses and reimbursement specialists provide an integrated and personal CARE approach. Biofusion is ACHC accredited.

Biogen Idec Weston, MA www.biogen.comBooth 507

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and hemophilia therapies. For more information, visit www.biogen.com.

38

Cadwell Laboratories, Inc. Kennewick, WA www.cadwell.comBooth 101

Established. Focused. Global. At Cadwell®, we are passionate about enabling quality, informed outcomes for your patient care by delivering efficient, quality neurodiagnostic and neuromonitoring solutions. We take pride in combining customer input with our employees’ expertise and USA-made components to provide the best solutions in the industry.

Catalyst Pharmaceuticals Coral Gables, FL www.catalystpharma.com Booth 212

Catalyst Pharmaceuticals, Inc., is dedicated to advancing therapies targeting rare neuromuscular and neurological diseases: Lambert - Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes, MuSK Myasthenia Gravis, Infantile Spasms. Catalyst will be launching a confirmatory study for the treatment of patients diagnosed with LEMS with its lead program Amifampridine Phosphate.

Coram CVS/specialty infusion services Denver, CO www.coramhc.com Booth 313

Together, Coram and CVS Specialty provide comprehensive infusion services to your patients. Whether they need in-home nursing services or medications shipped to your office, we can help. We work with both pharmacy and medical benefits.

Corinthian Reference Laboratory Benbrook, TX www.corinthianreferencelab.com Booth 107

CRL is a commercial diagnostic laboratory specializing in neurological disease detection. We specialize in epidermal nerve fiber density (ENFD) testing. ENFD testing offers patients objective evidence of a neuropathy which can hopefully lead to a more accurate diagnosis. For additional information, please contact Greg Davenport at 480-330-3684.

Demos Medical Publishing New York, NY www.demosmedpub.com Booth 316

For more than 25 years, Demos Medical Publishing has served the information needs of medical professionals.

We publish high-quality books and digital products for physicians and other healthcare providers, and have established an international reputation for excellence in our core areas of neurology, physical medicine and rehabilitation, pathology, and oncology.

Diplomat Flint, MI www.diplomat.is Booth 117

Diplomat is the nation’s largest independent specialty pharmacy. We work with the entire health care ecosystem to connect patients who have chronic and rare conditions to medication, information and funding. Our high-touch and uniquely personal approach is backed by exceptional results in patient satisfaction, prescriber satisfaction, adherence rates and more.

Elsevier Philadelphia, PA www.elsevier.com Booth 515

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, and deliver better care.

Emory Genetics Laboratory Decatur, GA www.geneticslab.emory.eduBooth 215 EGL specializes in genetic diagnostic testing, with 46 years of clinical experience and board-certified laboratory directors and genetic counselors reporting out cases. EGL offers a combined 1100 molecular genetics, biochemical genetics, and cytogenetics tests under one roof and custom testing for all medically relevant genes, for domestic and international clients.

FUJIFILM VisualSonics, Inc Toronto, ON www.vevomd.com Booth 503

FUJIFILM VisualSonics, Inc is the undisputed world leader in real-time, high-resolution, ultra-high frequency ultrasound imaging; providing the greatest level of anatomical detail for the tiniest of structures. Our cutting edge technology allows clinicians at the world’s most prestigious hospitals and medical centers to make diagnoses and improve patient care in pediatrics, dermatology, musculoskeletal and vascular fields like never before possible. For the first time you can see the 30% of the body missed by conventional ultrasound, and when it comes to healthcare, seeing more matters!

39

GE Healthcare Wauwatosa, WI www.gehealthcare.com Booth 109

GE is making a new commitment to health. Healthymagination will change the way we approach healthcare, with more than 100 innovations all focused on addressing three critical needs: lowering costs, touching more lives and improving quality. For more information, visit our website at www.gehealthcare.com.

Gene DX Gaithersburg, MD www.genedx.com Booth 108

GeneDx specializes in genetic testing for rare hereditary disorders. Our mission is to make clinical testing available to people with rare genetic conditions and their families. Most of our tests include full gene analysis by DNA sequencing, the gold standard of genetic testing. We invite you to explore our site, where you will find comprehensive information and all of our paperwork. Please note that GeneDx does not provide Direct-to-Consumer testing. All tests must be ordered, and results sent to a health care provider, usually a physician or genetic counselor. Families are encouraged to present our material to their health care providers who can evaluate the appropriateness of testing.

Global Medical Imaging Charlotte, NC www.gmi3.com Booth 415

GMI, founded in 2002, sells and supports a wide range of clinical ultrasound systems. Known for our transparency, we are the largest non-OEM ultrasound company in the US. We serve our customers with confidence knowing that we can provide the best solutions for your ultrasound imaging and service needs.

Grifols USA, LLC Los Angeles, CA www.grifolsusa.com Booth 102

Grifols is a global healthcare company whose mission is to improve the health and well-being of people around the world. We have three primary divisions – Bioscience, Diagnostic and Hospital – that develop, produce and market our innovative products and services to medical professionals in more than 100 countries around the world.

Hawaiian Moon Clearwater, FL www.aloecream.biz Booth 513

Say goodbye to dry skin with Hawaiian Moon Organic Aloe Cream!

International Biophysics Corporation Austin, TX www.afflovest.com Booth 116

International Biophysics brings to market innovative, disruptive medical devices and technologies that improve treatment therapies and patient outcomes. The AffloVest is the first truly portable High Frequency Chest Wall Oscillation (HFCWO) vest that promotes airway clearance and lung secretion mobilization prescribed in the treatment of respiratory diseases like Bronchiectasis, Cystic Fibrosis, MS, ALS, and other neuromuscular diseases. Reimbursed by Medicare, Medicaid and private insurance, Made in the USA, and shown to contribute to improved lung function scores.

Ipsen Biopharmaceuticals Basking Ridge, NJ www.ipsen.com Booth 216

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases.

Jari Electrode Supply Gilroy, CA www.jarisupply.com Booth 104

Jari Electrode Supply is a supplier of the finest quality electrodes for EMG and EEG use. We feature disposable monopolar needle electrodes, disposable inject able needle electrodes, and disposable detachable concentric needle electrodes. We also have available reusable needle and surface electrodes along with accessories for the neurologists. Our courteous sales staff is ready to serve your needs. Call Jari Electrode Supply at (800) 745-1934 or check out our website www.jarisupply.com

40

KabaFusion, LLC Cerritos, CA www.kabafusion.com Booth 110

KabaFusion is a pharmacist-owned, patient-focused team of professionals with extensive experience in home infusion and specialty infusion therapy. Services are provided from our pharmacies in CA, TX, NJ, MA and IL. Our pharmacists, nurses, and reimbursement specialists work as a team to provide your patient with compassionate, efficient, and reliable care.

KEGO FMI (Faith Medical Inc) Lexington, KY www.kegodiagnostics.comBooth 508

KEGO is an international distributor of sleep and neurodiagnostic supplies. With locations in the USA and Canada, KEGO is your national “One Stop Shop”, representing major manufacturers of sleep and neurodiagnostic products. Check out the full line of KEGO products at www.kegodiagnostics.com. What can KEGO do for you today?

LGMD Consortium Seattle WA www.lgmd-diagnosis.org Booth 5

The LGMD Consortium consists of 7 LGMD foundations that joined forces to tackle areas common interests. The free sequencing program, LGMD-diagnosis.org, is the consortium’s effort to rapidly diagnose patients. Members: Cecil B Day Family, Coalition to Cure Calpain 3, Jain Foundation, Kurt+Peter Foundation, LGMD2D Foundation, LGMD2I Fund, and McColl-Lockwood Laboratory.

Mayo Medical Laboratories Rochester, MN www.MayoMedicalLaboratories.com Booth 312

Mayo Medical Laboratories is a global reference laboratory operating within Mayo Clinic’s Department of Laboratory Medicine and Pathology. Our comprehensive neurology testing menu, as well as the expertise of Mayo Clinic neurologists, lab directors and genetic counselors, provides the detailed clinical information to diagnose and treat hundreds of neurological conditions.

MediMax Tech East Rancho Dominguez, CA www.medimaxtech.com Booth 112

Our company manufactures neurological, surgical and electrotherapy/chiropractic supplies and products. Since 2004, MMT has made it our mission to provide customers with highest quality medical products, cost effective savings and great customer service.

MEPs, LLC / Digitimer Ltd Ft. Lauderdale, FL www.digitimer.com Booth 210

MEPS, LLC is the exclusive source in North America for the clinical products offered by Digitimer Ltd.(UK). On display will be the extremely popular Digitimer high output electrical stimulators including designs where the output waveform shape can be modified during a stimulating sequence.

Merz Pharmaceuticals, LLC Raleigh, NC www.merzusa.com Booth 314

Merz Neurosciences is dedicated to delivering a better total experience to patients and physicians in neurosciences. We strive to deliver meaningful treatment options and a better patient experience in order to meet the needs of each person we serve. Merz Neurosciences is an important contributor to the U.S. neurosciences space, offering a well-balanced product portfolio that includes the neurotoxin Xeomin® (incobotulinumtoxinA)

MT Pharma America Long Beach, CA www.MT-Pharma-US.comBooth 113 The Medical Affairs team at MT Pharma America serves as the primary interface with the medical and scientific community through scientific and clinical information exchange, research, and engagement with patient advocacy groups. As a subsidiary of Mitsubishi Tanabe Pharma Corporation, our heritage of developing innovative compounds dates back to 1678.

MVAP Medical Supplies Newbury Park, CA www.mvapmed.com Booth 417

MVAP Medical Supplies Inc. is the very proud distributor of over 7,000 EEG, EMG, IOM, as well as Sleep and Respiratory supplies, making us a One-Stop-Shop supplier! We continue to offer the latest, most innovative products at very competitive prices, and customer satisfaction is our #1 goal! Come visit us at booth #417

41

Natus Neurology Incorporated Middleton, WI www.natus.com Booth 301

Built on the expertise of the most widely used and trusted names in neurodiagnostics – Nicolet, XLTEK, Dantec – Natus Neurology offers reliable electrodiagnostic systems that collect, retrieve, and review patients’ EMG and EP data, guiding critical decisions regarding patient care.

Nihon Kohden America Irvine, CA www.us.nihonkohden.com Booth 308

The MEB-2300 is the latest and most innovative EMG/ NCS/EP system from Nihon Kohden. Its scalable configuration offers either a six or twelve channel amplifier and up to two electrical stimulators. The MEB-2300 is designed with advanced software packages and timesaving features to maximize workflow while ensuring data integrity.

Nova Labs South Jordan, UT www.novalabs.co Booth 505

Nova Labs is a laboratory that specializes specifically in the diagnosis of small fiber neuropathy. We pride ourselves on our knowledge, concise reporting, patient care, and education. Our state of the art facility is located in Templeton, CA. Our goals are to partner with physicians to help further along the diagnosis and treatment of small fiber neuropathy.

Option Care Bannockburn, IL www.optioncare.comBooth 409 Option Care offers industry-leading expertise, access, and support in IG home infusion therapy. Each year, we provide more than 80,000 IG home infusions across the country. We are contracted with more than 800 health plans and have a >96% success rate in overturning benefit denials.

PromptCare Clark, NJ www.promptcare.netBooth 514

Established in 1985, PromptCare provides leading home infusions and respiratory services. We have pharmacies located throughout the Northeast, including our recent

acquisition of Boston Home Infusion in Massachusetts. PromptCare’s specialized home Immunoglobulin program is focused on improving clinical outcomes and overall quality of life of the patients we treat.

RDL Reference Laboratory Los Angeles, CA www.rdlinc.com Booth 413

RDL, an autoimmune CLIA laboratory, provides quality assays for the practicing/academic Neurologist. We offer the most exclusive and extensive Myositis Antibody Testing: Our unique Anti-HMGCR Ab (Statin Myonecrosis), anti-cN-1A Ab (sIBM), and the Myomarker 3 panel, clearly leading the Myositis Ab field.

Rochester Electro-Medical, Inc. Lutz, FL www.rochestermed.com Booth 213

For over 50 years, Rochester Electro-Medical has been your best source for affordable, high-quality neurodiagnostic products and personalized service. Featured products include NEW lines of monopolar and concentric needles and disposable electrodes that offer unbeatable value and performance. Stop by for information on our full range of electrodes and supplies.

Sanofi Genzyme Cambridge, MA www.genzyme.com Booth 401

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

Sarepta Therapeutics Cambridge, MA www.sareptatherapeutics.comBooth 512

Sarepta Therapeutics is a biopharmaceutical company focused on developing innovative RNA-targeted therapeutics. Harnessing the power of cutting-edge technology, our rapidly advancing clinical programs, including our exon-skipping platform for Duchenne muscular dystrophy, position us on the threshold of realizing the potential of our proprietary RNA-based technology.

42

Shire Bannockburn, IL www.shire.com Booth 307

At Shire our purpose is to enable people with life-altering conditions to lead better lives. To fulfill this purpose, we have combined with Baxalta to become the leading global biotechnology company focused on rare diseases and highly specialized conditions.

The ALS Association Washington, DC www.alsa-national.orgBooth 6 Leading the fight to treat and cure ALS through global research and nationwide advocacy while also empowering people with Lou Gehrig’s Disease and their families to live fuller lives by providing them with compassionate care and support.

The Electrode Store Enumclaw, WA www.electrodestore.com Booth 411

The Electrode Store is an ISO13485-certified manufacturer and distributor of a wide variety of needle electrodes, surface electrodes, leads, gels and accessories for EMG and EEG procedures. Products offered include proprietary Electrode Store designs and quality 3rd party products. Competitive prices and quick shipping. Order online or call 800-537-1093.

Therapath Neuropathology New York, NY www.Therapath.comBooth 414 Therapath provides specialty neuropathology testing. Diagnostic services include epidermal nerve fiber density testing, sweat gland nerve fiber density testing, muscle biopsy analysis, and peripheral nerve biopsy analysis.

Ultragenyx Pharmaceutical Inc. Novato, CA www.ultragenyx.com Booth 416

Ultragenyx is a development-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases. Ultragenyx has licensed rights to aceneuramic acid extended release and its potential use in treating GNE Myopathy from Nobelpharma, AAI Pharma, and the HIBM Research Group.

University of Missouri Columbia, MO www.medicine.missouri.edu/neurology/Booth 111 Department of Neurology at MU Health Care is an academic health center located in Central Missouri with rapidly expanding, 20+ provider practice, serving 18,000 patients/year. We are seeking board certified/board eligible Neuromuscular physician. J1 waiver eligible position. Excellent compensation plan with productivity based incentive!

University of Utah - Cutaneous Nerve Lab Salt Lake City, UT www.medicine.utah.edu/neurology/neuroBooth 315 The University of Utah Cutaneous Nerve Laboratory serves as a clinical diagnostic laboratory as well as a core resource for NIH, foundation-funded and industry-sponsored research projects. Our laboratory staff have over 25 years of combined experience in cutaneous innervation evaluation.

US WorldMeds Louisville, KY www.usworldmeds.com Booth 106

US WorldMeds holds a fundamental belief that our science has the potential to improve patients’ lives. Our portfolio of products and development projects reflects our commitment to bring innovative therapies to patients with unmet medical needs. Please visit our US WorldMeds booth to learn more.

WR Medical Electronics Company Maplewood, MN www.wrmed.comBooth 506 Looking for the standard in Autonomic Function Testing? You’ve come to the right place. WR Medical Electronics equipment provides quantitative assessments of the sympathetic and parasympathetic nervous system. Perform QSART, Valsalva maneuver, HRDB, and head-up tilt analysis. All testing is non-invasive, standardized, and simple-to perform. Stop by for information!

43

Industry FriendsAllerganUnrestricted Educational Grant: Chemodenervation In-Kind Equipment

BioCure RxUnrestricted Educational Grant:Ask The Expert - Immune Mediated NM DisordersExhibit Hall Passport

Cadwell Laboratories, Inc.Digital AdvertisingAANEM News AdvertisingNotebook Pages in Meeting Guide In-Kind Equipment

Coram CVS/specialty infusion servicesExhibit Hall Passport

Corinthian Reference LaboratoryConference Bag SponsorshipDigital Advertising

CSL BehringUnrestricted Educational Grant: From Primary Demyelination to Nodopathy

Emory Genetic LaboratoryExhibit Hall Passport

FUJI VisualSonics, IncIn-Kind Equipment

GE HealthcareIn-Kind Equipment

Gene DXExhibit Hall Passport

Global Medical ImagingIn-Kind Equipment

Ipsen BiopharmaceuticalsUnrestricted Educational Grant: Ultrasound Guidance for NeurotoxinsUnrestricted Educational Grant: Ask The Expert - Spasticity

Kabafusion, LLCExhibit Hall Passport

LGMD ConsortiumColumn Wrap Advertising

MEPs, LLCAANEM News AdvertisingExhibit Hall Passport

Natus NeurologyResident & Fellow Bootcamp SponsorshipIn-Kind Equipment

Option CareExhibit Hall Passport

Ultragenyx Pharmaceutical, Inc.Unrestricted Educational Grant: Genetics of Hereditary Neuropathy and Myopathy

WR Medical Electronics CompanyIn-Kind Equipment

Platinum Plus Support($125,000+)GrifolsEducational Support:CIDP Knowledge Self-AssessmentExaminationWiFi SponsorshipExhibit Hall Passport

Silver Level Support($45,000 - $64,999)Alnylam PharmaceuticalsIndustry Forum

Bronze Level Support($25,000 to $44,999)ShireName Badge Neck Wallet SponsorshipDigital AdvertisingOnsite Meeting Guide AdvertisingWebsite AdvertisingCoffee Break Sponsorship

MT Pharma AmericaMeeting App SponsorshipPresident’s Reception SponsorshipSilent Auction SponsorUnrestricted Educational Grant: Motor Neuron Disease and its Mimics

Alexion PharmaceuticalsAANEM Annual Meeting SupportMGFA Scientific Metting Support

The AANEM would like to acknowledge the following companies for their 2016 support and contributions to theAANEM and the 2016 AANEM Annual Meeting.

THANK YOU to our Corporate Supporters

The AANEM would like to acknowledge the following companies for their 2016 support and contributions to theAANEM and the 2016 AANEM Annual Meeting.

44

Abstract Poster Viewing

All abstract research posters will be on display in the Hall of Research (Exhibition Center A & B, 2nd level) from Wed., Sept. 14 through Friday, Sept. 16. Stop by after the Thursday and Friday Plenary sessions to meet the authors and discuss their research.Poster session I: Sept. 15, 11:30 AM – 12:30 PM: Authors of posters (1-109)Poster Session II: Sept. 16, 11:30 AM – 12:30 PM: Authors of posters (110-207)

Technologist Member Award

POSTER HALL LAYOUT

Resident & Fellow Member Recognition Award Winners

President’s Research Initiative Award Winners

International Federation of Clinical Neurophysiology Fellowship Recipients

AANEM Foundation International Fellowship Award Recipients

Non-CME Abstracts

217208 209 210 211 212 213 214 215 216

207 206197 198 199 200 201 202 203 204 205

196 195 194 193 192 191 190 189 188179 180 181 182 183 184 185 186 187

178 177 176 175 174 173 172 171 170161 162 163 164 165 166 167 168 169

160 159 158 157 156 155 154147 148 149 150 151 152 153

146 145 142 141 140 139 138 136 134122 123 126 127 128 129 130 132 133

121 120 119 118 117 115 114 113 112102 103 104 105 106 107 109 110 111

101 100 99 98 97 96 95 94 9383 84 85 86 87 88 90 91 92

82 80 79 78 77 76 75 74 7364 65 66 67 68 69 70 71 72

63 62 61 60 59 58 57 56 5546 47 48 49 50 51 52 53 54

45 44 43 42 41 40 39 38 3728 29 30 31 32 33 34 35 36

27 26 25 24 23 2215 17 18 19 20 21

14 13 12 11 10 9 81 2 3 4 5 6 7

Entrance to Hall

Entrance to Hall

45

Golseth Young Investigator Award Winner

($1,000, complimentary travel, accommodations and meeting registration)

Santoshi Billakota, MD, a Clinical Neurophysiology and Epilepsy fellow at Columbia Presbyterian Medical Center in New York, is the recipient of this year’s Golseth Young Investigator Award for the abstract, “Utility of Ultrasound in Diagnosis of Carpal Tunnel Syndrome” (abstract #1).

The 2016 Golseth Young Investigator Award, honoring AANEM founding member, Dr. James Golseth, is presented annually for original research in neuromuscular and EDX medicine. The AANEM Foundation has been funding the award since 1998.

Best Abstract Award Winner

($500, complimentary travel, accommodations, and meeting registration)The Best Abstract Award will be presented to Todd Levine, MD, for the abstract, “Response to Intravenous Immunoglobulin in Patients with Chronic Inflammatory Demyelinating Polyneuropathy: The Insights Quality Improvement Project” (abstract #2).

Best Abstracts Runners-Up

The runners-up for Best Abstract are Jeffrey Allen, MD, for the abstract, “Challenges in the Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy: A Review of Patients Treated with Intravenous Immunoglobulin From a Specialty Pharmacy Database”(abstract #3) and Gary Gallagher, MD, for the abstract “The Safety of Nerve Conduction Studies in Patients with Central Lines” (abstract #4).

Abstract Award Winners’ Reception

Thursday, September 15Multi-Level • 1.5 CME/CEU • 5:30 - 7:00 PMHall of Research - Exhibition Center C, 2nd level

Enjoy an evening celebrating research! Socialize with abstract authors while enjoying snacks, wine, and refreshments. Poster authors will be available for discussion and abstract award winners will present their industry-leading research. 5:30 PM - 6:30 PM: Abstract Award winners’ research Presentations

5:30 PM Golseth Young Investigator Award: Santoshi Billakota, MD 5:45 PM Best Abstract Todd D. Levine, MD 6:00 PM Best Abstract Runner-up Jeffrey A. Allen, MD 6:15 PM Best Abstract Runner-up Gary W. Gallagher, MD 6:30 PM - 7:30 PM: President’s Research Initiative Award winners’ Presentations and Discussion.Led by AANEM President, Dr. Vern Juel.

Printed Abstracts Available

Scientific abstracts for the 2016 AANEM 2016 Annual Meeting are printed with the September 2016 issue of Muscle & Nerve, and will be available in PDF format at www.aanem.org/meeting.

View 2016 abstracts online at ww.aanem.org/meeting. Click on the blue “2016 Abstracts” button to download.

Santoshi Billakota, MD

Todd Levine, MD

Abstract Award RecipientsOver 200 scientific abstracts were approved for presentation at the AANEM 2016 Annual Meeting. The AANEM Program Committee chose two outstanding abstracts out of the hundreds to be honored with the Golseth Young Investigator Award and the Best Abstract Award.

Submit Research for the 2017 Meeting

The abstract submission process for the 2017 AANEM Annual Meeting will open on

January 1, 2017. Plan now to submit your research by the March 15 deadline.

Details about the submission process are online atwww.aanem.org/meeting by clicking on “Abstracts”.

46

Congratulations to the 2016 Achievement Award RecipientsThe AANEM Achievement Awards will be presented during the 2016 Annual Meeting on Friday, Sept. 16 during the morning plenary session. Join us at this special recognition ceremony as we honor the following recipients.

Lifetime Achievement Award: Lawrence H. Phillips, II, MD

Lawrence H. Phillips, II, MD, will receive the 2016 Lifetime Achievement Award for the depth and breadth of his contributions to the fields of EDX and NM medicine

“This is the organization I have invested the most significant amount of my time in over the years, and being honored by this organization I’ve devoted so much to, means everything to me,” said Dr. Phillips.

Distinguished Physician Award: John D. England, MD

John D. England, MD, is the recipient of the 2016 Distinguished Physician Award, which recognizes a member for superior achievements as a clinician, educator, and association volunteer.

“What I wanted to do my whole life was be a doctor. To be called a ‘distinguished physician’ is the highest honor I can think of,” said Dr. England. “It means I take good care of patients, and I have the interests of healthcare in mind. I hope that I have advanced the field in some small way, and helped provide guidance to other professionals.”

Distinguished Researcher Award: Andrew J. Haig, MD

Andrew J. Haig, MD, is the recipient of the 2016 Distinguished Researcher Award honoring an AANEM member who has made continuous significant contributions to clinical neurophysiology research.

“I’ve gotten many awards in my life, but this is the one that kind of took my breath away,” said Dr. Haig. “These are the people who know my research and appreciate what I’m doing. For the rest of my life, this will be the award that will mean the most to me.”

Advocacy Award: Enrica Arnaudo, MD, PhD

Enrica Arnaudo, MD, PhD, is the recipient of the 2016 Advocacy Award, in recognition of extraordinary contributions to increase public awareness and advocate to government entities or insurance companies regarding the role of EDX medicine in diagnosis and treatment.

“I have a passion for health policy,” said Dr. Arnaudo. A firm believer in grassroots advocacy, she said, “We need to join together, to build relationships inside and out of the medical profession. I believe we can improve the landscape for physicians if we do it collectively, with a unified voice.”

Robert C. Griggs, MD – Honorary Member

The AANEM grants Honorary Membership to recognize nonmember physicians or scientific investigators who are major contributors to the fields of electrodiagnosis, neurophysiology, or neuromuscular disease through teaching, research, and/or scholarly publications. The 2016 Honoree is Robert C. Griggs, MD.

“I am grateful to the AANEM for this flattering recognition,” said Dr. Griggs. “I consider the AANEM an important organization for my subspecialty of neuromuscular disease. I also count many members of the

AANEM as highly esteemed colleagues and collaborators.”

Lawrence H. Phillips II, MD

John D. England, MD

Andrew J. Haig, MD

Enrica Arnaudo, MD

Robert C. Griggs, MD

47

President’s Research Initiative Awards($500) The 2016 President’s Research Initiative Award topic chosen by President Vern C. Juel, MD is “Quantitative Assessment in NM Disease.” This year 10 abstracts were chosen to receive the award (abstracts #5 -14). The authors will present their research and take part in a moderated discussion with President Juel at the Abstract Award Winner’s Reception on Thursday, Sept. 15 at 5:30 PM in the Hall of Research (Exhibition Center C).Congratulations to this year’s award winners:

Ultrasound Differentiation of Charcot–Marie–Tooth Type 1 And Chronic Inflammatory Demyelinating Polyradiculoneuropathy (Abstract #5)Mingsheng Liu, Liying Cui, Jingwen Niu (Beijing, China)

PK/PD Modeling And Simulation of 3,4-Diaminopyridine Base In Patients With Lambert–Eaton Myasthenia Syndrome(Abstract #6)Jeffrey Guptill (Durham, NC), Nilay Thakkar (Chapel Hill, NC), Charles Peloquin (Gainesville, FL), Kathy Ales, David Jacobus, Laura Jacobus (Princeton, NJ), Michael Cohen-Wolkowiez (Durham, NC), Daniel Gonzalez (Chapel Hill , NC), DAPPER Study Group

Innovative Assessment of Muscle Injury Using Electrical Impedance Myography (Abstract #7)Benjamin Sanchez (Brookline, MA), Shama Iyer (Baltimore, MD), Jia Li (Boston, MA), Richard Lovering (Baltimore, MD), Seward Rutkove (Boston, MA)

Longitudinal Evaluations of Upper Extremity 3d Reachable Workspace in Pompe Disease by Kinect Sensor (Abstract #8)Divya Reddy, Sarah Humbert (Loma Linda, CA), Evan de Bie, Alina Nicorici (Sacramento, CA), Jay Han (Irvine, CA)

Use of Kinect Sensor to Determine Reachable Work Space After Botulinum Toxin Injection for Upper Limb Spasticity (Abstract #9)Karina Del Rosaria, Linda Johnson (Sacramento, CA), Evan de Bie, Lisa Williams, Brian Barry (Santa Cruz, CA), Jay Han (Orange , CA)

Size Index Revisited: Verification by Increased Number of Subjects (Abstract #10)Masahiro Sonoo, Go Ogawa (Tokyo, Japan), Erik Stalberg (Uppsala, Sweden)

Electrical Impedance Myography of Face and Neck Muscles: Establishing Normative Values (Abstract #11)Courtney McIlduff, Sung Yim, Adam Pacheck, Seward Rutkove (Boston, MA)

Autonomic Dysfunction in Sensory Neuronopathies: A Quantitative Sudomotor Axon Reflex Evaluation (Abstract #12)Alberto Martinez, Ingrid Faber, Maximiliano Carneiro, Carlos Martins Jr, Guilherme Gasque, Jose Domingues, Anamarli Nucci, Marcondes França Jr (Campinas, Sao Paulo, Brazil)

Reliability of Bedside Ultrasound of Muscle and Diaphragm Thickness in Critically Ill Children (Abstract #13)Kay Wei Ping Ng (Singapore, Singapore), Alexander Dietz, Ryan Johnson, Michael Shoykhet, Craig Zaidman (St. Louis, MO)

Soleus-H Reflex Study in Spasticity, Dystonia, and Contracture in Children: Impact of Botulinum Toxin Injection (Abstract #14)Debabrata Ghosh (Columbus, OH)

48

Resident and Fellow Members Recognition

($200) The Resident and Fellow Member Reward

The Resident & Fellow Member Recognition Award encourages physicians in training to submit research for

the opportunity to be recognized for their efforts.To qualify for the Resident and Fellow Member

Recognition Award, the first author must be a resident or fellow member of the AANEM at the time of submission

and be available to present at the meeting.

Congratulations to the following 2016 recipients:

Fouad Alghamdi, MBBSSyeda Alqadri, MD

Jose David Avila, MDGrayson Beecher, MD

Brian Chau, MDSleiman El Jamal, MD

Rocio Garcia-Santibanez, MDCharles Gervais, MD

Francisco Gomez, MDRohit Gummi, BS

Jennifer Jaskiewicz, DONidhi Kapoor, MBBS

Elias Karroum, MD, PhDGupreet Khakh, MD

Nina Kim, MDChristopher Lamb, MD

Ikjae Lee, MDVictoria Levasseur, MD

David Lorance, MDAnza Memon, MDElie Naddaf, MD

Kay Wei Ping Ng, MBBS, MRCP, MmedRadhika Sampat, DOKaye Sedarsky, MD

Syed Shah, MBBS, MDShail Thanki, MD

Vanessa Tiongson, MDAmy Visser, MD

Lisa Williams, MDChristina Zaccarini, MD

Technologist Member Recognition Awards

The Technologist Member award is given to AANEM member technologists who are first author presenters of

accepted abstracts for the annual meeting.


Alaa Bouzhar, R.NCS.TFavio Bumanlag, R.NCS.T, CNCT

Kimberley Butler, CNCT

($1,000, complimentary meeting registration)

The AANEM Foundation Fellowship Award provides an opportunity for physicians who practice in economically developing countries to apply for funds to support their education through attendance at the AANEM Annual

Meeting. Up to five Foundation Fellowship Awards are granted annually. All applicants are also automatically

considered for awards offered through the North American Chapter of the International Federation of Clinical

Neurophysiology (IFCN).


AANEM Foundation AwardValeria Alvarez, MD, MSc (Argentina)

Vitor Marques Caldas, MD (Brazil)Ana Calzada-Reyes, MD, MSc (Cuba)

Christopher Constantino, MD (Philippines)Julianne Cordenonssi, MD (Brazil)

IFCN AwardLidia Charroo Ruíz, MD, MSc (Cuba)

Pradnya Dhargave, MD (India)Hazem El-Karabaty, MD (Egypt)

Yodeisy Ferrer González, MD (Cuba)Joel Gutierrez, MD, PhD (Cuba)

Joao Kouyoumdjian, MD, PhD (Brazil)Luciana León Cejas, MD (Argentina)

Ming Li, MD (China)Mingsheng Liu, MD (China)

Alberto Martinez, MD (Brazil)Hebatallah Rashed, PhD (Egypt)Alexandre Recchia, MD (Brazil)

Fernando Raúl Rivero Martinez, MD (Cuba)Lita Vargas, MD (Argentina)

Jhoana Marie Zambrano, MD (Philippines)Dongqing Zhu, MD (China)

Foundation and IFCN Fellowship Awards

49

THANK YOUAANEM Foundation Contributors

(Contributions received between September 19, 2015-July 31, 2016)Helping advance neuromuscular and electrodiagnostic research and education

Legacy Contribution:Edward H. Lambert Lectureship Endowment($100,000)

Vanda Lennon, MD, PhD

Gold Gift($1,000-$2,499)

James Leonard, MD

Silver Gifts($250-$999)Jitendra Baruah, MD Gregory Carter, MD, MS David Chkhartishvili, MD, PhD Upinder Dhand, MD Raghav Govindarajan, MDPeter Grant, MD Laurie Gutmann, MD Lois Nora, MD, JD, MBAPerry Richardson, MDDevon Rubin, MD David Saperstein, MD Liane Sher, MD Eric Sorenson, MD Mary Spires, MD, PT, MAJeffrey Strommen, MD

Bronze Gifts($50-$249)

Raymond Alcuri, MD Syeda Alqadri, MD Prasunamba Amaraneni, MDMichael Andary, MD, MS Carmel Armon, MD, MS, MHSEzzedine Attig, MD, MSc, FRCP(C)Frank Audoor Bassam Bassam, MD Mark Bernhard, DO Samuel Bierner, MD Shawn Bird, MD Andrea Boon, MD Brian Bowyer, MD Randall Braddom, MD, MS

Milton Calima, MD Faye Chiou-Tan, MD Dong Cho, MD Albert Clairmont, MBBS Philip Davenport, MSc, MD Michael DeMarco, DO Mark Domroese, MD, PhD Jutta Eichelman, MD, PhD Michael Ellerbusch, MD Jose Fernandez, MD, PhD Edward Fine, MD Evelia Gomez Wong. MDAndrew Haig, MD Somkiat Hemtasilpa, MDHolli Horak, MD James Howard, MD Charles Jablecki, MD Albert Janerich, MD Caroline Klein, MD, PhD Alex Krob,MD Kerry Levin, MD Christina Marciniak, MD Janice Massey, MD Michelle McFarlane, MD Daniel Menkes, MD Matthew Murnane, MD Charu Nagar, MD David Oliveri, MD Tracy Park, MD Atul Patel, MD Bridget Patterson-Marshall, MDDouglas Pavlak, MD William Pease, MD Clark Pinyan, MD, MPH David Polston, MD Kevin Puzio, MD Alicia Quiroga, MD Brenda Riggott Coswin Saito, MD, MPH Donald Sanders, MD George Schakaraschwili, MDMarcy Schlinger, DO Zachary Simmons, MD David Simpson, DO, MS Masahiro Sonoo, MD, PhD Henry Spindler, MD Ramaswami Sundar, MD

Christina Taddeo, MD Loretta VanEvery, MD John Vlattas, MD Douglas Wayne, MD Louis Weimer, MD Faren Williams, MD Carl Yacoub, MD Amy Zarrin, MD, PhD

Foundation Gifts(up to $50)

W. David Arnold, MD Kay Barry, RN, MSElham Bayat, MD Giovanni D’Aprile Bryan DeSouza, MD Honorio Dispo, MD Mercedes Gil Marques, MDM. Faseeh Hadidi, MD William Jens, DO Mohammad Kabiraj, MBBS, M.Phil, PhD Rana Kayal, MD Cheryl Kelty, CNCT, R.NCS.TSam-Gyu Lee, MD, PhD Megan Leitch, MD Dora Leung, MD Penny Mayes-Gregg, CNCT, R.NCS.TSarah Miller, MD Nilofer Nisar, MD Jess Olson, MD Amanda Rabquer, MD Carlos Rangel, MD Veronica Rodriguez, MD Jonathan Rutchik, MD, MPH Robert Smith, MD, PhD Seneca Storm, MD David Tempest, MD, MA Rana Tenorio, MD Karen Tobin, MD Vincent Tranchitella, MDJun Tsugawa, MD Eroboghene Ubogu, MDMervat Wahba, MD

Donate to the AANEM Foundation at www.aanemfoundation.orgThe AANEM Foundation is a 501(c)(3) nonprofit corporation. Your donation is tax-deductible to the extent allowed by law.

50

Platinum Corporate Circle Contributor

Silver Corporate Circle Contributor

Bronze Corporate Circle Contributor

Raymond Alcuri, MD Michael T. Andary, MD, MS Elda Grace Gabuya Anota Michele L. Arnold, MD W. David Arnold, MD Kay Barry, RN, MSJitendra K. Baruah, MD Bassam A. Bassam, MDElham Bayat, MDSamuel M. Bierner, MDCyril O. Burke, MDMilton C. Calima, MDGregory T. Carter, MD, MS C. Y. Chang, MDAnthony E. Chiodo, MDFaye Y. Chiou-Tan, MDAlbert C. Clairmont, MBBSGiovanni Antonio D’Aprile Philip A. Davenport MSc, MDMichael DeMarco, DOBryan X. DeSouza, MDHonorio T. Dispo, MDMark E. Domroese MD, PhDJutta M. Eichelman MD, PhDJose M. Fernandez MD, PhDRobert J. Friedman, MDKristi K. George, MDMercedes Gil Marques, MDPeter A. Grant, MDM Faseeh Hadidi, MDSomkiat Hemtasilpa, MDLewis J. Herzbrun, MD

Holli A. Horak, MDJames F. Howard, MDSusan L. Hubbell, MD, MS Melvin Landon Hughes, R.NCS.T, R.EEG. T.William Jens, DOShawn Jorgensen, MDRana Kayal, MDCheryl R. Kelty, CNCT, R.NCS.TJohn C. Kincaid, MDKiril Kiprovski, MDCaroline M. Klein, MD, PhDAlex Krob, MDFrancis P. Lagattuta, MDSam-Gyu Lee, MD, PhDMegan Moran Leitch, MDJames A. Leonard, MDLorri J. Lobeck, MDChristina M. Marciniak, MDJanice M. Massey, MDJoseph H. Mayer, MDDaniel L. Menkes, MDMichael J. Mrochek, MDMichael C. Munin, MDCharu Nagar, MDDavid J. Oliveri, MDJess W. Olson, MDTracy A. Park, MDAtul T. Patel, MDBridget Patterson-Marshall, MDDouglas M. Pavlak, MDWilliam S. Pease, MD

Daniel Phillips, MD, BSEE/BMEAdam D. Quick, MDAmanda Rabquer, MDVeronica Rodriguez, MDKyle W. Ruffing, MDJonathan S. Rutchik, MD, MPHMohammad A. Saeed, MD, MS George V. Schakaraschwili, MDMorteza Shamsnia, MDDrasko Simovic, MDDavid A. Simpson, DO, MSHenry A. Spindler, MDMary Catherine Spires, MD, PT, MASeneca A. Storm, MDMillie Suk, JD, MPPKaren E. Tobin, MDBryan E. Tsao, MDJun Tsugawa, MDEroboghene E. Ubogu, MDMichael A. Valente, DO, MSHALoretta M. VanEvery, MDVettaikorumakankav Vedanarayanan, MD, FRCPCCarmen Rita Ventocilla, MDJohn S. Vlattas, MDBenjamin S. Warfel, MDDouglas A. Wayne, MDLouis H. Weimer, MD Faren H. Williams, MD Carl Ramses Yacoub, MD Amy R. Zarrin, MD, PhD

Advocacy Contributors

Corporate Circle ContributorsHelping advance neuromuscular and electrodiagnostic

research and education

51

AANEM CME Programming: It is the policy of the AANEM to ensure balance, independence, objectivity and scientific rigor in all of its educational activities. This program is for scientific and educational purposes only and will not, directly or indirectly, promote the interests of any commercial interest. All CME sessions that are offered as part of the official AANEM Annual Meeting program are developed and implemented solely by the AANEM Annual Meeting education planning committees and the AANEM staff. Education planning committees are responsible for: identifying educational needs and gaps between current and ideal performance, competencies and patient outcomes; determining teaching methods; selecting presentation topics, choosing faculty, establishing objectives; and determining format for the presentation of content. Educational materials cannot contain any advertising, corporate logo, trade name, or product-group message. All scientific research referred to, reported or used in support of justification of a patient care recommendation will conform to generally accepted standards of experimental design, data collection and analysis. Speakers are requested to provide a balanced view of therapeutic options, using generic names in presentations to contribute to impartiality. If content includes trade names, speakers are instructed to incorporate the trade names from several companies.

Specific disclosure information for all speakers, planning committee members and course chairs participating in the 2016 Annual Meeting is provided in the Disclosure Appendix at the back of this Meeting Guide.

Industry Forums: Industry Forums are commercially supported educational activities held in conjunction with the AANEM Annual Meeting. These satellite symposia sessions are not part of the AANEM’s official annual meeting program and are planned by an outside company or party. These sessions are clearly labeled as Industry Forums to allow the participant to be fully aware of any bias in the presentations. Seating at sessions is limited, and food is provided by the AANEM to Industry Forum attendees on a first-come, first-served basis.

Save the date

2017 AANEM ANNUAL MEETING

SEPTEMBER 13-16, 2017PHOENIX, ARIZONA

REGISTRATION OPENSJUNE 1, 2017

www.aanem.org/meeting

September 13 - 16

AANEM ANNUAL MEETING

Phoenix, Arizona

AANEM

Laboratory Accreditation

Check out AANEM’s new and improved Electrodiagnostic Laboratory Accreditation online application!

• User-friendly initial application process• Annual Compliance Report now online• Laboratories who are nearing the end of their 5-year

cycle will be contacted by AANEM to go through the online reaccreditation application

For more information, please go towww.aanem.org/Practice/EDX-Laboratory-Accreditation

52

DISCLOSURE APPENDIX

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The AANEM is accredited by the ACCME to provide continuing medical education for physicians.

It is the policy of the AANEM to ensure balance, independence, objectivity and scientific rigor in all of its educational activities. All participating speakers, planning committee members, and authors are required to disclose to the program audience any financialrelationships with proprietary entities producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients that is related to the subject matter of this program. Spouse/partner relationships with commercial interests are also disclosed. Disclosure information was reviewed in advance in order to manage and resolve any possible conflicts of interest. All conflicts of interest have been resolved in accordance with ACCME Standards for Commercial Support℠.

2016 Annual Meeting Disclosure InformationDisclosure information for all faculty, planning committee members and staff (and their spouse/partner) participating in this activityand/or the planning of this activity is provided below.

FacultyName (Last, First, M.I.) Degree(s) Commercial Interest(s) Financial Relationship(s)Allen, Jeffrey A. MD None N/AAlpers, Joshua P. MD None N/AAlter, Katharine E. MD None N/AAmato, Anthony A. MD None N/AAndary, Michael T. MD, MS Allergan SpeakerBarkhaus, Paul E. MD None N/ABassam, Bassam A. MD None N/ABaute, Vanessa MD None N/ABerini, Sarah MD None N/ABeydoun, Said R. MD Alexion, CSL Behring, Daiichi

Pharma, GSKBaxalta, Grifols, XeonPort

Research Grants

Speaker, Advisory Board, Consultant

Bird, Shawn J. MD None N/ABönnemann, Carsten G. MD None N/ABoon, Andrea J. MD None N/ABorg-Stein, Joanne P. MD None N/ABromberg, Mark B. MD, PhD None N/ABurns, Ted M. MD None N/ABusis, Neil A. MD None N/ACampbell, William W. MD None N/ACartwright, Michael S. MD None N/AChaudhry, Vinay MD None N/AChawla, Jasvinder P. MBBS, MD, MBA None N/AChen, Robert MBBChir, MSc, FRCPC None N/AChiodo, Anthony E. MD None N/AChoi, Joseph M. MD None N/ACudkowicz, Merit E. MD, MSc AstraZeneca, Mitsubishi,

Biohaven, Genentech, Cytokinetics, BiogenNIH, ALSA, and ALSAFAC

Consultant

Independent ContractorDastgir, Jahannaz DO None N/ADel Toro, David R. MD None N/ADillingham, Timothy R. MD, MS None N/ADimachkie, Mazen M. MD Baxalta, Catalyst, CSL Behring,

Mallinckrodt, Novartis, Octapharma, NuFactorAlexion, BioMarin, Catalyst, CSL Behring, FDA/OPD, GSK, Grifols, MDA, NIH, Novartis, TMA

Speaker’s Bureau, Consultant

Research Grants

Donofrio, Peter D. MD None N/ADubin, Andrew H. MD, MS None N/AFeinberg, Joseph H. MD None N/AFerrante, Mark A. MD None N/AFranklin, Mary E. R. EEG T., CNCT None N/AGibbons, Christopher H. MD, MMSc None N/AGilchrist, James M. MD None N/A

53

Gooch, Clifton L. MD None N/AGoodman, Brent P. MD None N/AGovindarajan, Raghav MD None N/AGrant, Peter A. MD None N/AGuptill, Jeffrey T. MD US NIH, NINDS and NICHD,

MGFA, Grifols Foundation, UCB Biosciences Inc.Jacobus Pharmaceuticals, Marinus,Momenta, Serimmune, and UCB

Research Grants

Consultant

Gutmann, Ludwig MD None N/AGwathmey, Kelly G. MD None N/AHaig, Andrew J. MD Haig et al., Consulting LLC Owner/EmployeeHallett, Mark MD None N/AHan, Jay J. MD None N/AHarrison, Taylor B. MD None N/AHayat, Ghazala R. MD None N/AHegde, Madhuri PhD., FACMG None N/AHenning, Phillip T. DO None N/AHobson-Webb, Lisa D. MD Aerpio Therapeutics (Spouse) EmploymentHommel, Alyson M. MD None N/AHorner, Michael N. DO None N/AHoward, James F. MD Alexion Pharmaceuticals

Alexion Pharmaceuticals, argenx,Alpha Cancer Technologies, Toleranzia

Research GrantsConsultant

Inkpen, Peter MD None N/AIzenberg, Aaron MD None N/AJacobson, Ryan D. MD None N/AJuel, Vern C. MD None N/AKafaie, Jafar MD, PhD None N/AKatirji, Bashar MD None N/AKatzberg, Hans D. MD CSL Behring, Grifols, Octapharma Consultant, Medical

Advisory Boards, Honorarium, Research Grants

Kennelly, Kathleen D. MD, PhD None N/AKesner, Vita G. MD, PhD None N/AKimura, Jun MD None N/AKissel, John T. MD Novartis, BioMarin, Cytokinetics,

CSl Behring, AveXis, Ionis, AxelaCare, Quintiles

Consultant

Krzesniak-Swinarska, Monika MD None N/AKuntz, Nancy L. MD None N/ALagattuta, Francis P. MD None N/ALaidlaw, Ann T. MD None N/ALeep Hunderfund, Andrea N. MD None N/ALevin, Kerry H. MD None N/ALevine, Todd D. MD Grifols, Baxalta

Baxalta, CSL Behring, Grifols

NuFactor Specialty Pharmacy

Speaker's BureauResearch/Educational GrantsConsultant

Lewis, James CNCT, R.NCS.T None N/ALiang, Chiawen L. MD None N/ALiewluck, Teerin MD None N/ALittle, Ann A. MD None N/ALondon, Zachary N. MD None N/ALou, Jau-Shin MD, PhD, MBA None N/AManzi, Suzanne M. MD Applied Biologics

Boston ScientificConsultantSpeaker's Bureau

Massey, Janice M. MD None N/AMauermann, Michelle L. MD None N/AMauricio, Elizabeth A. MD None N/AMenkes, Daniel L. MD None N/AMeriggioli, Matthew N. MD Novartis ConsultantMiller, Timothy M. MD, PhD Biogen, Ionis Research Grant/FundingMilone, Margherita MD, PhD None N/AMorris, Jerry CNCT, MS, R.NCS.T. None N/AMunin, Michael C. MD None N/A

54

Nandedkar, Sanjeev D. PhD Natus Medical Inc. EmployeeNarayanaswami, Pushpa MBBS, DM None N/ANorbury, John W. MD None N/APasnoor, Mamatha MD None N/APatel, Atul T. MD Allergan, Merz

Allergan, Merz, IpsenSpeaker's BureauClinical Trials

Pease, William S. MD None N/APeltier, Amanda C. MD None N/APerlman, Seth J. MD None N/APestronk, Alan MD None N/APinyan, Clark W. MD, MPH None N/APolston, David W. MD None N/APreston, David C. MD None N/APrice, Raymond S. MD Grifols

OptumcareSpeakerConsultant

Quan, Dianna MD None N/ARaabe, Winfried A. MD None N/ARichardson, James K. MD None N/ARichardson, Perry K. MD None N/ARobinson, Lawrence R. MD None N/ARoss, Mark A. MD None N/ARubin, Devon I. MD None N/ASalajegheh, Mohammad MD None N/ASanders, Donald B. MD None N/ASaporta, Mario MD, PhD None N/ASchulman, Kevin A. MD Genentech ConsultantShefner, Jeremy M. MD, PhD Cytokinetics, Ionis, Biogen ConsultantShetty, Teena MD GE NFL

GE, Abbott, ChembioMedical Advisory BoardResearch Grant

Shook, Steven J. MD None N/ASiddiqi, Zaeem A. MD, PhD None N/ASimmons, Zachary MD None N/ASimpson, David A. DO, MS None N/ASimpson, David M. MD None N/ASkalsky, Andrew J. MD None N/ASmith, Benn E. MD None N/ASorenson, Eric J. MD None N/ASouayah, Nizar MD None N/ASpiegelberg, Teresa CNCT None N/AStaff, Nathan P. MD, PhD None N/AStolp, Kathryn A. MD, MS None N/AStrakowski, Jeffrey A. MD None N/AStrommen, Jeffrey A. MD None N/AStubblefield, Michael D. MD None N/ASucher, Benjamin M. DO None N/ASuk, Millie JD, MPP None N/ATeener, James W. MD None N/ATilton, Ann H. MD Ipsen Investigator and ConsultantTranchitella, Vincent J. MD None N/ATsao, Bryan E. MD None N/AVedanarayanan, Vettaikorumakankav

MD, FRCPC None N/A

Walker, Francis O. MD Terason, Monarch Medical, Viasys Interest free equipment loans

Warinner, Peter Q. MD None N/AWinter, Carrie None N/AZaidman, Craig MD None N/AZelnik, Danielle L. MD None N/A

StaffName (Last, First, M.I.) Degree(s) Commercial Interest(s) Financial Relationship(s)Adkins, Shirlyn JD None N/AKreps, Victoria None N/AMickelson, Mindy None N/AReilly, Karen None N/AWhite, Amy None N/A

55

PlannersName (Last, First, M.I.) Degree(s) Commercial Interest(s) Financial Relationship(s)Amato, Anthony A. MD Novartis, Akshi, Biogen,

AcceleronBest Doctors

Advisory Committee/Review PanelConsultant

Avila, Jose David MD None N/ABassam, Bassam A. MD None N/ABaute, Vanessa MD None N/ABierner, Samuel M. MD None N/ABoon, Andrea J. MD None N/ACaress, James B. MD None N/ACartwright, Michael S. MD None N/AChawla, Jasvinder P. MBBS, MD, MBA None N/ADesai, Urvi G. MD UCB Speaker/ TeacherFarheen, Amtul S. MD None N/AFeinberg, Joseph H. MD None N/AGallagher, Gary W. MD None N/AGiles, Elizabeth A. CNCT None N/AGovindarajan, Raghav MD None N/AHehir, Michael K. MD None N/AHobson-Webb, Lisa D. MD Aerpio Therapeutics

CLS Behring(Spouse) EmploymentSite PI

Horner, Michael N. DO None N/AHoward, Ileana MD None N/AInkpen, Peter MD None N/AIrwin, Robert W. MD None N/AJenkins, Jeffrey G. MD None N/AJorgensen, Shawn MD None N/AJuel, Vern C. MD None N/AKneiser, Mary K. MD None N/AKrzesniak-Swinarska, Monika MD None N/ALagattuta, Francis P. MD None N/ALesher, John MD None N/ALi, Jin MD, PhD None N/ALittle, Ann A. MD None N/ALondon, Zachary N. MD None N/ALou, Jau-Shin MD, PhD, MBA None N/AMilone, Margherita MD, PhD None N/ANelson, Andy A. MD None N/ANowacek, Dustin MD None N/APeltier, Amanda C. MD None N/APinyan, Clark W. MD, MPH None N/ARaheja, Divisha MD None N/ARamsey, Pati L. CNCT, R.NCS.T None N/ARichardson, Perry K. MD Allergan Speaker/ TeacherRusso, Mary J. CNCT, R.NCS.T,AS,BS None N/ASaeed, Tabassum MD None N/ASaffarian, Mathew DO None N/ASakamuri, Sarada MD None N/AScherer, Katalin MD None N/ASchwarz, Renee A. CNCT None N/AShieh, Perry B. MD, PhD BioMarin, Biogen, Sarepta,

Cytokinetics, Novartis, MarathonConsultant

Shook, Steven J. MD None N/ASkalsky, Andrew J. MD Medtronic, Mallinckrodt ConsultantSouayah, Nizar MD Grifols Speaker/ TeacherSpires, Mary C. MD None N/AStrakowski, Jeffrey A. MD None N/ATsao, Bryan E. MD None N/AVenkatesh, Yedatore S. MD None N/AWagle, Binod MBBS, MD None N/AWalker, Francis O. MD Natus, Terason Interest free equipment loanZaidman, Craig MD None N/A

56

www.cadwell.com 509.783.6503 509.735.6481

Notes:

57

www.cadwell.com 509.783.6503 509.735.6481

Notes:

58

www.cadwell.com 509.783.6503 509.735.6481

Notes:

59

www.cadwell.com 509.783.6503 509.735.6481

Notes:

60

Committee MembersANNUAL MEETING COORDINATIONWilliam S. Pease, MD, ChairAnthony A. Amato, MDMichael S. Cartwright, MDJasvinder P. Chawla, MBBS, MD, MBAIleana Howard, MDRobert W. Irwin, MDVern C. Juel, MDJau-Shin Lou, MD, PhD, MBAVincent J. Tranchitella, MD

NEUROMUSCULAR UPDATE COURSE COMMITTEEJasvinder P. Chawla, MBBS, MD, MBA, ChairBassam A. Bassam, MDSamuel M. Bierner, MDJames B. Caress, MDAmtul S. Farheen, MDGary W. Gallagher, MDMichael K. Hehir, MDZachary N. London, MDMargherita Milone, MD, PhD

Dustin Nowacek, MDAndrew J. Skalsky, MD

PROGRAM COMMITTEEAnthony A. Amato, MD, Co-ChairRobert W. Irwin, MD, Co-ChairUrvi G. Desau, MDElizabeth A. Giles, CNCTRaghav Govindarajan, MDMary K. Kneiser, MDFrancis P. Lagattuta, MDPati L. Ramsey, CNCT, R.NCS.TMathew Saffarian, DOKatalin Scherer, MDMary C. Spires, MD, PT, MABryan E. Tsao, MDFrancis O. Walker, MD

SPECIAL INTEREST GROUP/SYMPOSIA COMMITTEEJau-Shin Lou, MD, PhD, MBA, ChairVanessa Baute, MDJoseph H. Feinberg, MDMichael N. Horner, DOAmanda C. Peltier, MD, MSDivisha Raheja, MD

Perry K. Richardson, MDNizar Souayah, MD

WORKSHOP COMMITTEEIleana Howard, MD, ChairJeffrey G. Jenkins, MDJin Li, MD, PhDAnn A. Little, MDAndy A. Nelson, MDClark W. Pinyan, MD, MPHMary J. Russo, CNCT, R.NCS.T, AS,BSTabassum Saeed, MDRenee A. Schwarz, CNCT, R. NCST., R. EEG T., R. EP T.,C.M.E.T.Perry B. Shieh, MD, PhDYedatore S. Venkatesh, MDBinod Wagle, MBBS, MD

AANEM BOARD OF DIRECTORSPresident Vern C. Juel, MDSecretary-Treasurer Anthony E. Chiodo, MDPresident-Elect William S. Pease, MDPast President Vincent J. Tranchitella, MD

Historian John C. Kincaid, MDEric J. Sorenson, MDGregory T. Carter, MD, MSHolli A. Horak, MDAndrea J. Boon, MDYuen T. So, MD, PhDFaye Y. Chiou-Tan, MD

Executive Director Shirlyn A. Adkins, JD

ABEM BOARD OF DIRECTORSChair Kathryn A. Stolp, MD, MS Vice Chair Michael T. Andary, MD, MS Secretary Francis O. Walker, MDTreasurer John D. England, MDTimothy R. Dillingham, MD, MSPeter D. Donofrio, MD James F. Howard, Jr., MD Christina M. Marciniak, MD

Acknowledgments & Appreciation

Shirlyn A. Adkins, JD Executive [email protected]

Patrick Aldrich, CPA Finance [email protected]

Sarah Kramer Membership/Finance [email protected]

Victoria KrepsEducation [email protected]

Whitney LuttekeCommunications & Graphic [email protected]

Ruth Michel Administrative/Product [email protected]

Mindy MickelsonProject [email protected]

Laurie MonaCommunications [email protected]

Lori NiermanBoard Relations & Office [email protected]

Karen ReillyMeetings & Education [email protected]

Holly RennMember Engagement & Marketing [email protected]

Brenda L. Riggott Corporate Relations & Foundation [email protected]

Jacob Sokol IT [email protected]

Millie Suk, JD, MPP Health Policy [email protected]

Anna VredenburgProfessional Standards Senior [email protected]

Carrie Winter, RHIA Health Policy [email protected]

AANEM STAFF

61

Allen, Jeffrey A. 25,45Alpers, Joshua P. 14Alter, Katharine E. 6, 14, 18Amato, Anthony A. 22, 25, 60Andary, Michael T. 6, 17, 49, 50, 60

Barkhaus, Paul E. 6, 18Bassam, Bassam A. 24, 33, 49, 50, 60Baute, Vanessa 15, 16, 21, 60Berini, Sarah 29Beydoun, Said R. 24Billakota, Santoshi 45Bird, Shawn J. 17, 49Blackmore, Derrick 20Bönnemann, Carsten G. 28Boon, Andrea J. 17, 49, 60Borg-Stein, Joanne P. 14Borodovsky, Anna 20Bromberg, Mark B. 27Burns, Ted M. 8, 23Busis, Neil A. 25

Campbell, William W. 6, 17, 25, 34Cartwright, Michael S. 6, 18, 24, 30, 60Chaudhry, Vinay 25Chawla, Jasvinder P. 27, 60Chen, Robert 23Chiodo, Anthony E. 30, 50, 60Choi, Joseph M. 24Cornblath, David R. 20Cudkowicz, Merit E. 8, 23, 28

Dastgir, Jahannaz 28Del Toro, David R. 6, 26Dillingham, Timothy R. 21, 27, 60Dimachkie, Mazen M. 17Donofrio, Peter D. 6, 21, 25, 60Dubin, Andrew H. 26, 30

Feinberg, Joseph H. 22, 60Ferrante, Mark A. 6, 21, 25, 34Franklin, Mary E. 22

Gallagher, Gary W. 45, 60Gibbons, Christopher H. 30Gilchrist, James M. 33Gooch, Clifton L. 26Goodman, Brent P. 27Govindarajan, Raghav 22, 32, 49, 60Grant, Peter A. 32, 49, 50Guptill, Jeffrey T. 20, 29, 47Gutmann, Ludwig, 22Gwathmey, Kelly G. 24

Haig, Andrew J. 18, 34, 46, 49Hallett, Mark 33Han, Jay J. 8, 23, 47Harrison, Taylor B. 32Hayat, Ghazala R. 25Hegde, Madhuri 25Hehir, Michael K. 20, 60Henning, Phillip T. 30Hobson-Webb, Lisa D. 30

Hoke, Ahmet 20Hommel, Alyson M. 16Horner, Michael N. 17, 60Howard, James F. 20, 29, 49, 50, 60

Inkpen, Peter 30Izenberg, Aaron 24

Jacobson, Ryan D. 29Juel, Vern C. 3, 19, 23, 28, 34, 45, 47, 60

Kafaie, Jafar 15Katirji, Bashar 6, 14Katzberg, Hans D. 28Kennelly, Kathleen D. 33Kesner, Vita G. 17Kimura, Jun 6, 24Kissel, John T. 8, 28Krzesniak-Swinarska, Monika 16Kuntz, Nancy L. 14Kusner, Linda L. 20

Lagattuta, Francis P. 21, 50, 60Laidlaw, Ann T. 30Leep Hunderfund, Andrea N. 32Levin, Kerry H. 27, 49Levine, Todd D. 23, 45Lewis, James, 32Liang, Chiawen L. 14Liewluck, Teerin 24Little, Ann A. 15, 60London, Zachary N. 29, 60Lou, Jau-Shin 23, 32, 60

Mantegazza, Renato 20Manzi, Suzanne M. 17Massey, Janice M. 14, 26, 49, 50Mauermann, Michelle L. 30Mauricio, Elizabeth A. 22, 27Menkes, Daniel L. 17, 49, 50Meriggioli, Matthew N. 29Miller, Timothy M. 23Milone, Margherita 17, 24, 60Morris, Jerry 22Munin, Michael C. 17, 50

Nandedkar, Sanjeev D. 6, 32Narayanaswami, Pushpa 8, 19, 25, 32Norbury, John W. 15, 22, 26Nowak, Richard J. 20

O’Connor, Kevin C. 20

Pasnoor, Mamatha 32Patel, Atul T. 14, 27, 33, 49, 50Pease, William S. 19, 34, 49, 50, 60Peltier, Amanda C. 32, 34, 60Perlman, Seth J. 14Pestronk, Alan 25Pinyan, Clark W. 33, 49, 60Polston, David W. 16, 18, 49Preston, David C. 30

Price, Raymond S. 29

Quan, Dianna 29, 32

Raabe, Winfried A. 27Richardson, James K. 34Richardson, Perry K. 23, 28, 49, 60Robinson, Lawrence R. 6, 16, 21Robinton, John E. 31Ross, Mark A. 26Rubin, Devon I. 6, 15, 27, 49Russo, Melissa 20

Salajegheh, Mohammad Kian 24Sanders, Donald B. 6, 20, 33, 49Saporta, Mario 30Scherer, Steven S. 20Schulman, Kevin A. 8, 34Seidner, Adam 31Sengupta, Manjistha 20Shefner, Jeremy M. 23Sherrod, Mitchell 31Shetty, Teena 11, 14Shook, Steven J. 16, 18Siddiqi, Zaeem A. 14, 20Simmons, Zachary 21, 49Simpson, David A. 21, 49, 50Simpson, David M. 29Skalsky, Andrew J. 24, 60Smith, Benn E. 14, 16, 26Sorenson, Eric J. 33, 49, 60Souayah, Nizar 23, 60Spiegelberg, Teresa 15Staff, Nathan P. 30Stolp, Kathryn A. 26, 60Strakowski, Jeffrey A. 6, 15, 16, 18, 24Strommen, Jeffrey A. 17, 49Stubblefield, Michael D. 15, 16, 18, 29Sucher, Benjamin M. 17Suk, Millie 19, 32, 50, 60

Teener, James W. 15Tilton, Ann H. 11, 14Tranchitella, Vincent J. 25, 30, 32, 49, 60Tsao, Bryan E. 25, 50, 60

Vedanarayanan, Vettaikorumakankav 18, 33, 50

Walker, Francis O. 6, 15, 16, 27Walsh, Edward 20Warinner, Peter Q.14, 25, 30Winter, Carrie 19, 21, 60

Zaidman, Craig 14, 47Zelnik, Danielle L.16

Faculty & Speaker IndexA

B

C

D

F

G

N

L

M

K

J

I

H

O

Q

R

S

W

Z

T

V

P

62

INDICATIONS AND USAGEGAMMAGARD LIQUID is indicated as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).

CONTRAINDICATIONSGAMMAGARD LIQUID is contraindicated in patients who have a history of anaphylactic or severe systemic hypersensitivity reactions to the administration of human immune globulin. GAMMAGARD LIQUID is contraindicated in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity. Anaphylaxis has been reported with the intravenous use of GAMMAGARD LIQUID. [see Warnings and Precautions: Hypersensitivity]

WARNINGS AND PRECAUTIONSHypersensitivity: Severe hypersensitivity reactions may occur, even in patients who had tolerated previous treatment with human normal immune globulin. In case of hypersensitivity, discontinue GAMMAGARD LIQUID infusion immediately and institute appropriate treatment. GAMMAGARD LIQUID contains trace amount of IgA (average concentration of 37μg/mL). Patients with antibodies to IgA have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. GAMMAGARD LIQUID is contraindicated in patients with antibodies against IgA and a history of hypersensitivity reaction. [see Contraindications]Renal Dysfunction/Failure: Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur upon use of IGIV treatment, especially those containing sucrose.1 Acute renal dysfunction/failure has been reported in association with infusions of GAMMAGARD LIQUID. Assure that patients are not volume depleted prior to the initiation of infusion of GAMMAGARD LIQUID. In patients who are at risk of developing renal dysfunction, because of pre-existing renal insufficiency or predisposition to acute renal failure (such as diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs, etc.), administer GAMMAGARD LIQUID intravenously at the minimum rate of infusion practicable (not exceeding 3.3 milligram IgG/kg/min (<2 mL/kg/hr).Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk for developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of GAMMAGARD LIQUID and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation of GAMMAGARD LIQUID.Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia: Hyperproteinemia, increased serum viscosity and hyponatremia may occur in patients receiving GAMMAGARD LIQUID. It is critical to distinguish true hyponatremia from a pseudohyponatremia that is temporally or causally related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap; because treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity, and a predisposition to thromboembolic events.2

Thrombosis: Thrombosis may occur following treatment with immune globulin products, including GAMMAGARD LIQUID. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before

administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Boxed Warning]Aseptic Meningitis Syndrome (AMS): AMS may occur with IGIV treatment, and has been reported with intravenous use of GAMMAGARD LIQUID. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae. The syndrome usually begins within several hours to two days following IGIV treatment. AMS is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea and vomiting. Cerebrospinal fluid (CSF) studies frequently reveal pleocytosis up to several thousand cells per mm3, predominantly from the granulocytic series, and elevated protein levels up to several hundred milligram/dL, but negative culture results. Conduct a thorough neurological examination on patients exhibiting such symptoms and signs, including CSF studies, to rule out other causes of meningitis. AMS may occur more frequently with high dose (2 grams/kg) IGIV treatment and/or rapid infusion of IGIV.Hemolysis: GAMMAGARD LIQUID contains blood group antibodies that may act as hemolysins and induce in vivo coating of red blood cells (RBC) with immune globulin. This may cause a positive direct antiglobulin test [DAT (Coomb’s test)].3,4 Delayed hemolytic anemia can develop subsequent to GAMMAGARD LIQUID therapy due to enhanced RBC sequestration; acute hemolysis, consistent with intravascular hemolysis, has been reported.3-6 [see Adverse Reactions]The following risk factors may be related to the development of hemolysis: high doses (e.g., ≥2 grams/kg, single administration or divided over several days) and non-O blood group.3 Underlying inflammatory state in an individual patient may increase the risk of hemolysis3 but its role is uncertain.6,7 Monitor patients for clinical signs and symptoms of hemolysis [see Warnings and Precautions], particularly patients with risk factors noted above. Consider appropriate laboratory testing in higher risk patients, including measurement of hemoglobin or hematocrit prior to infusion and within approximately 36 to 96 hours post infusion. If clinical signs and symptoms of hemolysis or a significant drop in hemoglobin or hematocrit have been observed, perform additional confirmatory laboratory testing. If transfusion is indicated for patients who develop hemolysis with clinically compromising anemia after receiving IGIV, perform adequate cross-matching to avoid exacerbating on-going hemolysis.Transfusion-Related Acute Lung Injury (TRALI): Non-cardiogenic pulmonary edema (TRALI) has been reported in patients following treatment with IGIV products, including GAMMAGARD LIQUID. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Symptoms typically occur within 1 to 6 hours after treatment. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support.Transmittable Infectious Agents: Because GAMMAGARD LIQUID is made from human blood and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease agent. This also applies to unknown or emerging viruses and other pathogens. No confirmed cases of viral transmission or vCJD have been associated with GAMMAGARD LIQUID. All infections thought by a physician to possibly have been transmitted by this product should be reported by the physician or other healthcare provider to Baxalta US Inc., at 1-800-423-2090 (in the U.S.).Monitoring: Laboratory Tests: Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of BUN and serum creatinine, before the initial infusion of GAMMAGARD LIQUID and at appropriate intervals thereafter.Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies, because of the potentially increased risk of thrombosis.1,2

If signs and/or symptoms of hemolysis are present after an infusion of GAMMAGARD LIQUID, perform appropriate laboratory testing for confirmation.If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies and anti-HLA antibodies in both the product and patient’s serum.Interference with Laboratory Tests: After infusion of IgG, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield false positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test.

ADVERSE REACTIONSMMN: Intravenous Administration: The serious adverse reactions in the clinical trial for MMN were pulmonary embolism and blurred vision. The most common adverse reactions for MMN (observed in ≥5% of subjects) were headache, chest discomfort, muscle spasms, muscular weakness, nausea, oropharyngeal pain, and pain in extremity.

WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE See full prescribing information for complete boxed warning• Thrombosis may occur with immune globulin products, including

GAMMAGARD LIQUID. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. [see Warnings and Precautions]

• Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products including GAMMAGARD LIQUID. Renal dysfunction and acute failure occur more commonly with IGIV products containing sucrose. GAMMAGARD LIQUID does not contain sucrose.

• For patients at risk of thrombosis, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity. [see Warnings and Precautions]

GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10%Brief Summary of Prescribing Information. Please see package insert for full prescribing information.

T:6.875”

T:9.875”

GAMA15CDNY0872_A_Gammagard_MBS_6.875x9.875_April2015_r6.indd 1 8/31/15 4:35 PM

63

Clinical Trials Experience: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.MMN: Intravenous Administration: The safety of GAMMAGARD LIQUID was evaluated in 44 subjects with MMN who received a total of 983 infusions. Two serious adverse reactions, pulmonary embolism, and blurred vision occurred. In the study, among the 317 non-serious AEs, 176 were considered ARs. Of these, 126 were mild (transient discomfort that resolves spontaneously or with minimal intervention), 37 were moderate (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae) and 13 were severe (marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae). Adverse reactions with a frequency of ≥5% (defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period) are shown in Table 1.

Table 1. Adverse Reactions Occurring in ≥5% of MMN Subjects

Events

GAMMAGARD LIQUID Placebo

By Infusion N (%)

(N=983 Infusions)

By Subject N (%) (N=44

Subjects)

By Infusion N (%)

(N=129 Infusions)

By Subject N (%) (N=43

Subjects)

Headache 28 (2.85%) 14 (31.82%) 3 (2.33%) 2 (4.65%)

Chest Discomfort 3 (0.31%) 3 (6.82%) 0 (0.00%) 0 (0.00%)

Muscle Spasms 3 (0.31%) 3 (6.82%) 0 (0.00%) 0 (0.00%)

Muscular weakness 4 (0.41%) 3 (6.82%) 1 (0.78%) 1 (2.33%)

Nausea 28 (2.85%) 3 (6.82%) 2 (1.55%) 1 (2.33%)

Oropharyngeal pain 4 (0.41%) 3 (6.82%) 0 (0.00%) 0 (0.00%)

Pain in extremity 4 (0.41%) 3 (6.82%) 1 (0.78%) 1 (2.33%)

Postmarketing Experience: Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.

INTRAVENOUS ADRsHematologic Leukopenia Infusion Reactions Anaphylactic shock, anaphylactic reaction Neurological Transient ischemic attack, tremor, burning sensation Cardiovascular Hypotension, phlebitis, hypertension, chest pain Respiratory Pulmonary edema, dyspnea, oxygen saturation decreased Gastrointestinal Abdominal pain Integumentary Hyperhidrosis, allergic dermatitis Psychiatric Anxiety, insomnia

In addition to the events listed above which were observed for GAMMAGARD LIQUID, the following events have been identified for IGIV products in general: Renal Osmotic nephropathy Respiratory Cyanosis, hypoxemia, bronchospasm, apnea,

Acute Respiratory Distress Syndrome (ARDS) Integumentary Bullous dermatitis, epidermolysis, erythema multiforme,

Stevens-Johnson Syndrome Cardiovascular Cardiac arrest, vascular collapse Neurological Coma, seizures, loss of consciousness Hematologic Pancytopenia Gastrointestinal Hepatic dysfunction

DRUG INTERACTIONS Passive transfer of antibodies may transiently impair the immune responses to live attenuated virus vaccines such as mumps, rubella and varicella for up to 6 months and for a year or more to measles (rubeola). Inform the immunizing physician of recent therapy with GAMMAGARD LIQUID so that appropriate precautions can be taken.

USE IN SPECIFIC POPULATIONSPregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with GAMMAGARD LIQUID. It is also not known whether GAMMAGARD LIQUID can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Immune globulins cross the placenta from maternal circulation increasingly after 30 weeks of gestation. GAMMAGARD LIQUID should be given to a pregnant woman only if clearly indicated.Nursing Mothers: It is not known whether GAMMAGARD LIQUID is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when GAMMAGARD LIQUID is administered to a nursing woman.Pediatric UseMMN: Safety and effectiveness in pediatric patients with MMN have not been established.Geriatric Use MMN: GAMMAGARD LIQUID was administered intravenously for treatment of MMN in 5 subjects 65 years and above. There were insufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. [see Boxed Warnings and Warnings and Precautions]

REFERENCES1. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfusion Med Rev. 2003;17:241-251. 2. Katz U, Sheonfeld Y. Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 2005;14:802-8. 3. Wilson JR, Bhoopalam N, Fisher M. Hemolytic anemia associated with intravenous immunoglobulin. Muscle Nerve 1997;20:1142-1145. 4. Kessary-Shoham H, Levy Y, Shoenfeld Y, Lorber M, Gershon H. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration.

J Autoimmun 1999;13:129-135. 5. Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin:

a case series analysis. Transfusion. 2008; 48:1598-601. 6. Copelan EA, Strohm PL, Kennedy MS, Tuschka PJ, Hemolysis following intravenous immune globuline therapy. Transfusion 1986;26:410-412. 7. Kahwaji J, et al.; Acute hemolysis after High-Dose Intravenous Immunoglobin Therapy in Highly HLA Sensitized Patients. Clin J Am Soc Nephrol; 2009 (4):1993-97.

GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10%

Baxalta and Gammagard Liquid are trademarks of Baxalta Incorporated.Baxalta US Inc. Westlake Village, CA 91362 USA U.S. License No. 140 April 2015 USBS/1/14-0091(2)

T:6.875”

T:9.875”

GAMA15CDNY0872_A_Gammagard_MBS_6.875x9.875_April2015_r6.indd 2 8/31/15 4:35 PM

64

BAXALTA and GAMMAGARD LIQUID are trademarks or registered trademarks of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc. SHIRE is a trademark or registered trademark of Shire Pharmaceutical Holdings Ireland Limited or its affi liates. July 2016 USBS/1/16-0026

The first and only approved Multifocal Motor Neuropathy (MMN) treatment for adults to improve functioning1

Turning daily strugglesinto daily triumphs1-3

GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10%significantly improved grip strength and reduced disability1

• 60-week clinical study—largest randomized controlled trial in MMN to date1,2

• No sucrose; no added sugars, sodium, or preservatives1

IndicationGAMMAGARD LIQUID is indicated as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).

Selected Important Risk InformationWARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE• Thrombosis may occur with immune globulin products, including GAMMAGARD LIQUID. Risk factors may include

advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.

• Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products including GAMMAGARD LIQUID. Renal dysfunction and acute failure occur more commonly with IGIV products containing sucrose. GAMMAGARD LIQUID does not contain sucrose.

• For patients at risk of thrombosis, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

ADVERSE REACTIONS • The serious adverse reactions in the MMN (IV administration) clinical trial were pulmonary embolism and blurred

vision. The most common adverse reactions observed in ≥ 5% of patients in the clinical trials were: MMN (IV administration): Headache, chest discomfort, muscle spasms, muscular weakness, nausea, oropharyngeal pain, and pain in extremity.

Please see the GAMMAGARD LIQUID Brief Summary of Prescribing Information, including Boxed Warning, on the adjacent pages.

References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10%, prescribing information. Westlake Village, CA: Baxter Healthcare Corporation. 2. Data on fi le, Baxalta US Inc. 2011. 3. Sharrack B, Hughes RAC. The Guy’s Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler. 1999;5(4):223-233.

Visit booth #307 to learn about MMN diagnosis and treatment.

GAMA16CDNY6508_Single_Page_Ad_r8_PP.indd 1 7/29/16 10:33 AM

6902 corporate ad 7.5x10.indd 1 29/7/16 12:18thursday, 3:30 pm $100 amazon gift card friday, 10:15...

Documents